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 Gliomas are the most common primary brain tumor and are associated with a poor 
prognosis. Understanding the essential factors in the formation of these tumors is critical 
to improve the treatment of this disease. We report a thorough investigation of two potential 
drivers in the formation and maintenance of low-grade and high-grade gliomas – the kinase 
domain of BRAF and activated HBEGF. 
BRAF fusions have been observed in a majority of sporadic pilocytic astrocytomas, 
a low-grade glioma. In each fusion, the autoinhibitory domain of BRAF is lost, which 
results in activation via the retained kinase domain (BRAF-KD). Somatic cell gene transfer 
of the BRAF-KD alone did not cause tumors to develop; however, low-grade gliomas were 
detected in mice when combined with Ink4a/Arf loss. Pharmacologic inhibition of MEK 
and PI3K inhibited cell growth and induced apoptosis in astrocytes expressing BRAF-KD. 
Our findings demonstrate that the BRAF-KD can cooperate with Ink4a/Arf loss to drive 
the development of gliomas. 
 Heparin-binding epidermal growth factor (EGF)-like growth factor (HBEGF) is a 
ligand for the epidermal growth factor receptor (EGFR), one of the most commonly 
amplified receptor tyrosine kinases (RTK) in glioblastoma (GBM), a high-grade glioma.  
While HBEGF has been found to be expressed in a subset of malignant gliomas, its 
sufficiency for glioma initiation has not been evaluated. In this study, we demonstrate that
iv 
 
HBEGF can initiate GBM in mice in the context of Ink4a/Arf loss and Pten loss, and that 
these tumors are similar to the classical GBM subtype observed in patients. Isogenic 
astrocytes from these mice showed activation not only of Egfr but also the RTK Axl in 
response to HBEGF stimulation. Deletion of either RTK decreased the tumorigenic 
properties of HBEGF transformed cells. Silencing of HBEGF in vivo resulted in 
significantly increased survival suggesting that HBEGF may be a clinically relevant target. 
 The work outlined in this dissertation investigates the role of mutant BRAF and 
activated HBEGF in the initiation and maintenance of gliomas using a somatic cell gene 
transfer mouse model. These findings suggest that these proteins may be therapeutic targets 
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1.1 Glioma Statistics 
Gliomas are the most common primary brain tumors in adults, with a yearly 
incidence of six cases per 100,000 or approximately 20,000 patients diagnosed annually in 
the United States (Ostrom et al., 2014a). There are many types of gliomas, with a wide 
range of incidences and clinical outcomes. Pilocytic astrocytoma, a benign tumor to which 
the pediatric population is predisposed, has an annual incidence of 0.93 per 100,000 and a 
5-year survival rate of 94% (Ostrom et al., 2014b). In contrast, glioblastoma, a very 
aggressive tumor found mostly in older adults, has an annual incidence of 3.19 per 100,000 
and a 5-year survival rate of 5% (Ostrom et al., 2014a). Malignant brain tumors account 
for 2.4% of all cancer deaths each year (Therese A. Dolecek, Jennifer M. Propp, 2012).  
 
1.2 Glioma Classification 
 The World Health Organization (WHO) classification of gliomas is based solely on 
histological criteria and divided into four grades (Louis et al., 2007). Grades I and II are 
low-grade gliomas and Grades III and IV are high-grade gliomas. Grade I astrocytic tumors 
are pilocytic astrocytomas, which are slow-growing, circumscribed tumors detected in 





III gliomas show anaplasia and brisk mitotic activity and include the anaplastic 
astrocytomas and anaplastic oligodendrogliomas, while Grade IV gliomas are more 
commonly known as glioblastomas and are characterized by nuclear atypia, mitotic 
activity, cellular pleomorphism, vascular thrombosis, necrosis, and microvascular 
proliferation. Astrocytomas have prominent cytoplasmic processes and stain intensely with 
glial fibrillary acidic protein (GFAP), while oligodendrogliomas have small cytoplasm and 
round nuclei (Watanabe et al., 2002).  
In the next update of the WHO classification due this year, molecular markers will 
serve as important complementary diagnostic criteria (Louis et al., 2016). About 30% of 
glioblastomas with the proneural signature have isocitrate dehydrogenase (IDH1) 
mutations, which is associated with the genome-wide glioma cytosine-phosphate-guanine 
methylator phenotype (G-CIMP) (Noushmehr et al., 2010; Verhaak et al., 2010). Gliomas 
with mutations in alpha thalassemia / mental retardation syndrome X-linked (ATRX) are 
found in anaplastic astrocytomas while mutations in telomerase reverse transcriptase 
(TERT) are found in anaplastic oligodendrogliomas (Arita et al., 2013; Jiao et al., 2012). 
Concomitant loss of chromosomes 1p and 19q is a marker for improved survival and is 
associated with oligodendrogliomas (Smith et al., 2000). With the detection of IDH1 
mutations in the majority of low-grade gliomas, three categories have emerged: those with 
IDH1 mutations and 1p19q co-deletion (oligodendrogliomas), those with IDH1 mutations 
and p53 or ATRX mutations (astrocytomas), and those without IDH mutations (Balss et al., 
2008; Yan et al., 2009). With the widespread use of next generation genomics and 
proteomics, more molecular markers will likely be discovered to aid in diagnosis and 





1.3 Glioma Risk Factors 
 Close to 10% of patients have an inherited risk from genetic syndromes such as Li-
Fraumeni syndrome (p53 mutations), neurofibromatosis (NF1 and NF2 mutations), 
melanoma-astrocytoma syndrome (CDKN2A mutations), tuberous sclerosis (TSC1 and 
TSC2 mutations), and Cowden syndrome (PTEN mutations) (Goodenberger and Jenkins, 
2012). The vast majority of gliomas arise from a combination of complex environmental 
factors and genetic predispositions (de Andrade et al., 2001). Ionizing radiation is the only 
known risk factor that increases the chance for the development of gliomas (Mathews et 
al., 2013; Sadetzki et al., 2005). Other factors that increase risk, such as pesticides and cell 
phone usage, have been implicated but not conclusively shown (Frei et al., 2011; Hardell 
et al., 2013; Provost et al., 2007; Yiin et al., 2012). Meanwhile studies have shown that 
patients with increased immunological activity due to allergic conditions have a reduced 
glioma risk (Calboli et al., 2011; Linos et al., 2007; Wigertz et al., 2007). 
 
1.4 Clinical Presentation & Treatment of Glioma 
Brain tumors are associated with acute symptoms such as seizures, headaches, 
nausea, and vomiting. Evaluation of a patient with a suspected tumor involves imaging 
with either a CT or MRI scan, although the gold standard is histological examination either 
from biopsy or surgical resection. In glioblastoma, the standard of care is fractionated 
localized radiation therapy totaling 60 Gy combined with temozolomide, a cytotoxic DNA-
alkylating agent, following maximal surgical resection (Stupp et al., 2005). Favorable 
prognostic factors for malignant gliomas include younger age, extent of surgical resection, 





characteristics of the tumors also inform prognosis. Patients with mutations in the promoter 
of O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, show 
greater efficacy with temozolomide (Hegi et al., 2005). While efficacious in recurrent 
glioblastoma, use of the antivascular endothelial growth factor (VEGF) drug, 
bevacizumab, in newly diagnosed glioblastoma showed no further benefit over the standard 
treatment (Chinot et al., 2014; Friedman et al., 2009; Gilbert et al., 2014; Kreisl et al., 
2009). Other treatments that have been tested but failed to show improvement over the 
temozolomide and radiotherapy regimen include combinations of carmustine wafers, 
EGFR inhibitors, PDGFR inhibitors, and PKC inhibitors (Van Den Bent et al., 2009; 
Raymond et al., 2008; Westphal et al., 2003; Wick et al., 2010). Thus the median survival 
for patients with glioblastoma is still about 14 months with the current standard of care, 
highlighting the need for new therapies.  
For grade III gliomas, the presence of the 1p19q co-deletion, which usually defines 
the anaplastic oligodendrogliomas, dictates use of adjuvant radiation therapy and the 
chemotherapy regimen consisting of procarbazine, lomustine, and vincristine (PCV) 
(Cairncross et al., 1998; Ino et al., 2001). For patients without the 1p19q co-deletion, 
radiotherapy and temozolomide are usually indicated. Patients with grade III gliomas have 
median survivals on the order of years (3 for anaplastic astrocytoma and 15 for anaplastic 
oligodendroglioma).  
Low-grade gliomas usually present in younger patients compared to high-grade 
gliomas. As these are slower growing tumors, focal neural deficits from mass effect are not 
seen and many of these tumors are found incidentally from an imaging study for an 





patient with well-controlled seizures or no neurological deficits, it may be best to monitor 
rather than intervene. On the other hand, anaplastic gliomas can look like low-grade 
gliomas on MRI, and surgery allows for improved accuracy over needle biopsies in 
diagnosis, so intervention may be advantageous. Improved survival has been shown in 
patients with low-grade gliomas that underwent maximal safe resection (Jakola et al., 2012; 
McGirt et al., 2008).  
 
1.5 Genetics of Glioblastoma 
Characterizing tumors based on molecular markers has assumed a larger role 
recently, although challenges posed by tumor heterogeneity remain (Brennan et al., 2013; 
Parsons et al., 2008; Phillips et al., 2006; Verhaak et al., 2010). The Cancer Genome Atlas 
Network (TCGA) undertook a systematic approach to characterize glioblastomas based on 
analysis of several dimensions including DNA copy number, gene expression, and clinical 
treatment information. Alterations in three core pathways were revealed. Ninety percent 
have alterations in the receptor tyrosine kinase/RAS/phosphatidylinositol 3 kinase 
(RTK/RAS/PI3K) pathway with genetic alterations in phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN), epidermal growth factor receptor (EGFR), and 
platelet-derived growth factor receptor alpha polypeptide (PDGFRA) most frequent.  
Eighty-six percent have alterations in p53-associated pathways, represented by mostly 
cyclin-dependent kinase inhibitor 2A (CDKN2A) deletion and mutations in p53. Seventy-
nine percent have alterations in the retinoblastoma pathway, with alterations in CDKN2A 
and cyclin-dependent kinase 4 (CDK4) being the most common. Furthermore, 





mesenchymal subtype, and proliferative subtype, which is further classified into the neural 
and classical subtypes (Phillips et al., 2006; Verhaak et al., 2010). Clinically translating 
this wealth of knowledge is complicated because most of these genetic alterations, except 
for the RTKs, cannot be traditionally targeted with pharmacological agents, which focuses 
research on downstream effectors and alternate mutated pathways.  
Mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) have been 
found in more than 80% of grade II gliomas (diffuse astrocytomas), 70% of grade III 
gliomas (anaplastic astrocytomas and oligodendrogliomas), and 80% of secondary 
glioblastomas (Yan et al., 2009). IDH1 mutations have not been found in grade I gliomas 
(pilocytic astrocytomas) and only in a small subset of primary glioblastomas (3%), 
although it is possible that some of these were misclassified as primary because their 
genetic profiles were found to be similar to secondary glioblastomas (Toedt et al., 2011). 
Primary glioblastomas do not arise from a known precursor lesion and occur in older, adult 
patients, while secondary glioblastomas derive from a less malignant tumor and tend to 
occur in younger patients; histologically they are indistinguishable. While the distinction 
between primary and secondary glioblastomas was observed almost 70 years ago, it was 
not fully appreciated until different genetic alterations were identified (Scherer, 1940). 
Distinctly, primary glioblastomas have EGFR amplification, PTEN mutations, TERT 
mutations and loss of chromosome 10 (Ekstrand et al., 1992; Fujisawa et al., 2000; Ohgaki 
et al., 2004; Tohma et al., 1998). Secondary glioblastomas are characterized by IDH1 
mutations, p53 mutations, ATRX mutations, and 19q loss (Nakamura et al., 2000; 






1.6 BRAF in Glioma 
 About 88% of gliomas show alterations in the MAPK pathway. RAF is a MAPK 
kinase that consists of three family members: ARAF, BRAF, and CRAF. RAF serine-
threonine kinases become activated when associated with RAS and in turn activate 
MEK1/2 and consequently ERK1/2. In adult gliomas, BRAFV600E mutations are found in 
about 5% of high-grade gliomas as well diffuse low-grade gliomas (Basto et al., 2005; Chi 
et al., 2013; Davies et al., 2002; Kleinschmidt-DeMasters et al., 2013). Gene fusions 
involving BRAF have been found in over 80% of pilocytic astrocytomas and follow the 
motif of an in-frame fusion of the C-terminal BRAF kinase domain with loss of the N-
terminal autoinhibitory region (Cin et al., 2011). Surgery is usually curative for these low-
grade gliomas, but some tumors are not amendable to resection due to location while others 
reoccur after resection. In these cases radiotherapy and chemotherapy are indicated 
although special attention to the long-term effects of treatment must be paid as many of 
these patients are from the pediatric population (Douw et al., 2009). Part of the allure for 
using targeted therapy would be to spare the patient from the side effects of conventional 
therapy. Unfortunately, these BRAF fusions lack the codon 600 mutation, making them 
resistant to mutant BRAF inhibitors (Jones et al., 2009; Sievert et al., 2013). In fact, BRAF 
codon 600 mutations in pilocytic astrocytomas are found in less than 6% of patients, but 
are found in the majority of pleomorphic xanthoastrocytomas (up to 65%) and 
gangliogliomas (up to 75%) (Dahiya et al., 2013; Dias-Santagata et al., 2011; Schiffman et 
al., 2010; Schindler et al., 2011).  The sufficiency of the BRAF kinase domain to form low-






1.7 HBEGF in Glioma 
Aberrant activation of EGFR is seen in 45% of glioblastoma patients and is a 
hallmark of the classical subtype of glioblastoma (The Cancer Genome Atlas Network, 
2008; Verhaak et al., 2010). Expression of EGFR and the deletion mutant EGFRvIII, which 
is a truncated mutant lacking exons 2 to 7, are detected in about 40% of malignant gliomas 
(Wikstrand et al., 1997). EGFRvIII acts synergistically with PTEN to transform neural 
precursor cells as well as confer resistance to EGFR inhibitors (Li et al., 2009). One of the 
main transcriptional targets of EGFRvIII is an EGFR ligand, heparin-binding epidermal 
growth factor-like growth factor (HBEGF) (Li et al., 2014). HBEGF has been shown to be 
co-expressed with EGFR by immunohistochemistry in up to 40% of malignant gliomas 
(Mishima et al., 1998; Ramnarain et al., 2006). While its mitogenic effects in normal 
astrocytes and human glioma cells have been characterized, transformation of astrocytes 
by HBEGF in vitro or in vivo remains to be elucidated (Puschmann et al., 2014; Ramnarain 
et al., 2006).  
 
1.8 PDGFA in Glioma 
 PDGF autocrine stimulation is sufficient for the development of gliomas in mice 
(Uhrbom et al., 1998). PDGF signaling appears to be a crucial step to form 
oligodendrogliomas (Ozawa et al., 2014). Malignant gliomas express higher levels of 
PDGFRA, the receptor for PDGFA compared to lower grade gliomas or normal tissue 
(Takeuchi et al., 2004). Aberrations in the PDGFA signaling are considered a defining 
feature of the proneural subtype, which express oligodendrocytic development genes such 





positive prognostic marker in malignant gliomas (Martinho et al., 2009). As IDH1 
mutations have also been associated with the proneural subtype and better prognosis, there 
is likely overlap between PDGFA signaling and IDH1 mutations (Sturm et al., 2012). In 
fact, recently it was shown that IDH1 mutations can induce PDGFRA expression by 
relieving epigenetic suppression in the form of insulators (Flavahan et al., 2015). 
 
1.9 Mouse Models of Glioma 
 Animal models for gliomas have proven important in the development of 
therapeutics. Retrospective studies on the efficacy of carmustine and temozolomide found 
that the animal models were able to predict the modest survival benefit for carmustine and 
the better response seen with temozolomide compared to nitrosoureas (Amarasingh et al., 
2009; Hirst et al., 2013). There are two general types of mouse models – xenografts and 
genetically engineered models. Xenograft mouse models require the use of immune-
deficient mice for transplantation of human glioma cells that are either well-established in 
culture or patient-derived. Examples include the U251 and U87 glioma models where the 
cancer cells are implanted either subcutaneously or orthotopically in the brain 
(Camphausen et al., 2005; Radaelli et al., 2009). While these tumors show striking 
resemblance to human glioblastoma from immunohistochemical analyses, the utility of 
these models is limited due to the user-dependent differences in cell culture in vitro as well 
as the differences in growth in vivo in the absence of an immune system. These drawbacks 
do not affect genetically engineered mouse models, of which there are two main types – 
those with germline modifications and those generated through somatic cell gene transfer.  





the simian virus SV40 gene (Brinster et al., 1984). Microinjection of eggs with the viral 
gene caused random oncogenesis in the brain but also caused pathology in the kidneys and 
thymus. The first transgenic mouse model with brain specificity used the GFAP promoter 
to express the SV40 large T antigen to generate astrocytomas (Danks et al., 1995). Others 
have generated transgenic mouse models that are more clinically relevant using genetic 
lesions found in patients – such as NF1 loss and EGFRvIII expression. Using the GFAP 
promoter, expression of EGFRvIII was not sufficient to generate tumors and only with 
concurrent expression of HRas or loss of Ink4a/Arf and Pten were gliomas observed (Ding 
et al., 2003; Zhu et al., 2009). Loss of NF1, like loss of EGFRvIII, was not sufficient to 
form gliomas, but concurrent loss of p53 led to gliomagenesis (Reilly et al., 2000; Zhu et 
al., 2005).  
 Somatic cell gene transfer through the RCAS-TVA system addresses the main 
disadvantage of germline-modified transgenic models: the cost associated with developing 
a new strain of mice. With the RCAS-TVA model, oncogenes can be tested for sufficiency 
and necessity experiments by simply generating a new viral vector in a matter of days. 
Specific delivery of the oncogene is accomplished because of ectopic expression of the 
avian receptor TVA driven by a tissue-specific promoter such as Nestin or GFAP (Fisher 
et al., 1999). The RCAS-TVA glioma model has been used successfully with many putative 
and established oncogenes such as KrasG12D, PDGF-B, and BRAFV600E (Dai et al., 2001; 









The work outlined in this dissertation investigates the role of BRAF and HBEGF 
in the initiation and maintenance of gliomas using an in vivo model. BRAF fusion genes 
have been identified in greater than 80% of pilocytic astrocytomas that result in loss of the 
BRAF N-terminal auto-inhibitory domain and constitutive activation of the BRAF C-
terminal domain. While the importance of MAPK signaling in gliomas has been known for 
some time, the sufficiency of the BRAF kinase domain in the formation of gliomas in vivo 
remains an important question in the field. In Chapter 2, we show that the kinase domain 
of BRAF cooperates with CDKN2A loss to generate well-circumscribed, indolent gliomas 
in mice. We also demonstrate the efficacy of combined MEK and PI3K inhibition in 
astrocytes expressing the BRAF kinase domain.  
HBEGF has been observed to be upregulated in a significant subset of malignant 
gliomas, and HBEGF expression correlates with decreased survival, but in vitro or in vivo 
transformation by HBEGF has not been assessed. In Chapter 3, we show that HBEGF-
driven gliomas require loss of PTEN to generate malignant gliomas, while loss of CDKN2A 
led to initiation of low-grade gliomas. We uncovered a novel signaling pathway for 
HBEGF involving the receptor tyrosine kinase, Axl, and used transcriptome profiling to 
compare tumors driven by HBEGF, PDGFA, and BRAFV600E to the TCGA subtypes. We 
also demonstrate the feasibility of HBEGF as a clinical target using an in vivo tetracycline-
regulated model. 
After Chapter 4, supporting information involving HBEGF-, PDGFA-, and BRAF-
driven gliomas that could not be added due to space limitations during the publication 





unpublished data concerning our work to generate a tetracycline-responsive model for 
BRAFV600E-driven glioblastoma.  
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THE BRAF KINASE DOMAIN PROMOTES THE  
DEVELOPMENT OF GLIOMAS IN VIVO 
 
2.1 Preface 
This chapter is a reformatted version of a manuscript published in Genes & Cancer 
in January 2015. The work presented herein was completed with the following coauthors: 
Allie H. Grossmann, Sheri L. Holmen, and James P. Robinson. Reprinted with permission 
from Impact Journals, LLC. 
 
2.2 Introduction 
Aberrant RAS mitogen activated protein kinase (MAPK pathway) activation is a 
hallmark of gliomas (Abounader, 2009). Activation of this pathway occurs through 
mutations or amplifications in receptor tyrosine kinases or downstream signaling mediators 
such as RAS, RAF, MEK, and ERK (Kondo et al., 2004). Recently, a novel mechanism 
involving RAF fusion genes has been identified in pilocytic astrocytomas (PA) that allows 
for MAPK activation. In-frame fusions between FAM131B and BRAF have been observed 
in 2% of sporadic PA (Cin et al., 2011), fusions between SRGAP3 and RAF1 have also 
been found in 2% of sporadic PA (Jones et al., 2009), and fusions between KIAA1549 and 





2009; Jones et al., 2008; Sievert et al., 2009). The majority (>70%) of the KIAA1549:BRAF 
fusions occur between exon 16 of KIAA1549 and exon 9 of BRAF, but multiple different 
fusions have been identified (Cin et al., 2011; Tatevossian et al., 2010a). The presence of 
a BRAF fusion gene is now considered highly diagnostic for PA (Lawson et al., 2010). 
These fusions cause anchorage-independent growth when overexpressed in NIH3T3 cells 
(Jones et al., 2008, 2009) and cerebellar neural stem cell (NSC) cultures (Kaul et al., 2012). 
Cerebellar engraftment of NSCs expressing KIAA1549:BRAF in mice led to the formation 
of glioma-like lesions after a latency of 6 months (Kaul et al., 2012).  
In each fusion the N-terminus of RAF is replaced by FAM131B, SRGAP3 or 
KIAA1549, resulting in loss of the N-terminal autoinhibitory domain of RAF and 
constitutive activation of the MAPK pathway via the retained C-terminal kinase domain 
(BRAF-KD) (Figure 2.1). The specificity with which the C-terminus of RAF fuses to these 
different genes suggests that it is required for tumorigenesis in this context; however, the 
role of the C-terminal domain of BRAF within the fusions in glioma formation has not been 
validated. Expression of a BRAF kinase domain mutant carrying the V600E alteration 
(BRAF-KDVE) was sufficient to induce PA-like lesions in mice (Gronych et al., 2011). 
However, in patients, the BRAF kinase domain has not been found to be mutated in this 
manner in the context of a fusion gene. V600E mutations in full length BRAF are seen in 
a small percentage of PA (6%) (Chin et al., 1998; Lawson et al., 2010; Schiffman et al., 
2010; Zhang et al., 2013); however, they are much more common in grade II, and high-
grade malignant pediatric gliomas, accounting for 18% of grade II, 33% of grade III, and 
18% of grade IV tumors (23% grades II-IV) (Roussel, 1999).  We have previously 





gliomas in mice (Robinson et al., 2010). 
The development of small molecule serine-threonine kinase inhibitors 
(vemurafenib and dabrafenib) that specifically target mutant BRAF has revolutionized the 
treatment of melanoma, and clinical trials are underway for treatment of pediatric gliomas 
carrying the BRAFV600E mutation (NCT01748149, NCT02034110). However, 
paradoxically these inhibitors activate MAPK signaling in tumors that do not carry codon 
600 mutations, and new small molecule inhibitors designed to break this paradox do not 
inhibit BRAF fusion mutants at physiologically relevant doses (Sievert et al., 2013). 
Furthermore, mutations causing the truncation and loss of the BRAF autoregulatory 
domain are known to drive resistance to small molecule inhibitors that target the oncogenic 
codon 600 mutations (Kaul et al., 2012). 
In addition to constitutive MAPK activity, mutations targeting the p53/Rb cell cycle 
pathways are also seen in gliomas. In PA, loss of p16 correlates strongly with reduced 
senescence, increased cell division, and tumor progression (Kaul et al., 2012; Tatevossian 
et al., 2010b). Higher grade pediatric gliomas demonstrate constitutive MAPK activity, but 
this is almost always accompanied by homozygous deletion of the cyclin-dependent kinase 
inhibitor 2A (CDKN2A) locus (Schiffman et al., 2010). This locus encodes both p16 
(INK4a) and p14 (ARF) (Chin et al., 1998; Roussel, 1999). p16 functions to inhibit 
CDK4/6 mediated phosphorylation of the Retinoblastoma (Rb) protein, and its loss allows 
for unregulated cell division (Quelle et al., 1995). Loss of p14 leads to 
increased ubiquitination and destruction of p53 by HDM2 (Ivanchuk et al., 2008). 
Interestingly, 38.5% of PAs show loss of heterozygosity at 9q21, the location of the 





A follow-up study of PA patients receiving adjuvant therapy after surgery also found 14% 
of cases had both p16 loss and BRAF rearrangements (Horbinski et al., 2012). 
In the current study, we used the well-established RCAS/TVA glioma mouse model 
to assess the role of the BRAF-KD in glioma development in vivo. We show that although 
the BRAF-KD is not tumorigenic on its own, cooperation with Ink4a/Arf loss leads to the 
development of relatively indolent but highly atypical and cellular gliomas in vivo. 
 
2.3 Results 
2.3.1 The BRAF kinase domain promotes anchorage-independent growth. We 
previously demonstrated the transformative capacity of N-TVA/Ink4a/Arf-/- astrocytes 
infected with RCASBP(A) viruses containing CRAFΔ22W, BRAFV600E or KRASG12D, which 
form numerous colonies in soft agar (Robinson et al., 2010). To assess the transforming 
potential of the BRAF kinase domain BRAF-KD, we infected N-TVA/Ink4a/Arf-/- 
astrocytes with RCASBP(A)BRAF-KD and the full length BRAF with the V600E 
mutation, RCASBP(A)BRAFV600E (hereafter BRAF-FLVE). Gene delivery and expression 
was confirmed by immunoblotting (Figure 2.2A). Analysis of phosphorylated Erk 1/2 (P-
Erk) demonstrated elevated MAPK activation in cells expressing BRAF-KD (Figure 2.2B). 
Ink4a/Arf-deficient astrocytes expressing BRAF-KD or BRAF-FLVE proliferated more 
rapidly than the negative control; however, there was no significant difference between 
proliferation of BRAF-KD or BRAF-FLVE cells (P = 0.29; Figure 2.2C). Whereas 
Ink4a/Arf-deficient astrocytes did not form colonies in soft agar, expression of BRAF-KD 
or our positive control BRAF-FLVE, induced colonies demonstrating their ability to 





Interestingly, there was a statistically significant difference between the number of colonies 
formed by BRAF-KD and BRAF-FLVE expression (P = 0.04). 
2.3.2 The BRAF-kinase domain promotes transformation and tumor growth in 
vivo. A more stringent assay of tumorigenic potential is the ability to form tumors in vivo. 
The cell lines used for these orthotopic studies are syngeneic with the immunocompetent 
host mouse strain. Therefore, to assess tumorigenicity in vivo, 2 x 104 astrocytes were 
delivered intracranially to newborn mice, and the mice were monitored for signs of tumor 
formation. Ink4a/Arf-deficient astrocytes expressing mutant KRAS served as a positive 
control. Tumors formed within 3 weeks in 100% of mice injected with Ink4a/Arf-deficient 
astrocytes expressing KRASG12D (8 / 8) or the BRAF-KD (8 / 8). No tumors formed 
following the injection of uninfected astrocytes within this time frame. Histologically, the 
BRAF-KD tumors resembled highly cellular and invasive gliomas; both possessed a diffuse 
growth pattern but lacked the necrosis and endothelial hyperplasia typical of grade IV 
tumors, glioblastoma multiforme (GBM) (Figure 2.3). Expression of the BRAF-KD was 
confirmed using IHC for the HA epitope Tag (Figure 2.3). MAPK pathway activation 
within the tumors was assessed using IHC for P-Erk (Figure 2.3). All the tumors expressed 
the glial progenitor marker Nestin; however, expression of the glial fibrillary acidic protein 
(GFAP) was absent (Figure 2.3). 
2.3.3 Expression of the BRAF-KD in combination with Ink4a/Arf loss induces 
gliomas in mice. The RCAS/TVA system allows us to deliver genes to somatic Nestin-
TVA cells in vivo. This enables determination of the roles of specific genes in glioma 
initiation and progression. Using this system we previously validated the role of mutant 





that intracranial infection of newborn N-TVA/Ink4a/Arflox/lox mice with RCASBP(A) 
viruses containing BRAF-FLVE, KRASG12D or gain of function MEK (MEKGF) in 
combination with Cre leads to the development of high-grade gliomas of various subtypes 
and morphologies (Robinson et al., 2010, 2011). Here, we set out to determine if the 
BRAF-KD is sufficient to induce gliomas in vivo alone or in combination with Ink4a/Arf 
loss. Newborn N-TVA/Ink4a/Arflox/lox mice were infected intracranially with RCASBP(A) 
virus containing BRAF-KD and/or Cre, and survival was assessed over a 12-week period. 
All mice infected with RCASBP(A) viruses containing BRAF-KD (12 / 12), Cre (30 / 30) 
or BRAF-KD + Cre (29 / 29) survived the 12-week experimental period. Brain tissue from 
all injected mice was analyzed histologically. None of the mice infected with RCASBP(A) 
viruses containing BRAF-KD or Cre alone developed tumors; however, gliomas were 
detected in 21% (6 / 29) of mice injected with RCASBP(A) viruses containing BRAF-KD 
and Cre (Figure 2.4A). This incidence is not statistically different (P = 0.15) from our 
previously published experiments, where 38% (10 / 26) of mice injected with full length 
BRAFV600E and Cre viruses developed tumors; however, the mice with BRAF-FLVE-
induced tumors had to be sacrificed before 12 weeks due to tumor burden (Robinson et al., 
2010) whereas the BRAF-KD mice demonstrated no obvious symptoms (Figure 2.4B). 
Histologic analysis of the brains from the BRAF-KD cohort revealed the presence of 
tumors, which suggests a distinct progression from the BRAFV600E-induced tumors. The 
stark difference in the posthoc survival analysis of tumor-bearing BRAF-KD and BRAF-
FLVE mice (P < 0.001) as well as the lower level of P-Erk1 and P-Erk2 (P < 0.001) in 
astrocytes expressing BRAF-KD compared to BRAF-FLVE suggests that the BRAF-KD 





Histologically, the BRAF-KD Ink4a/Arf-/- tumors were highly cellular, with 
atypical nuclei and mitoses, similar to the BRAF-FLVE-induced tumors. In contrast to the 
BRAF-FLVE-induced tumors, the BRAF-KD–induced tumors showed a more 
circumscribed, less invasive border. Furthermore, the BRAF-KD-induced tumors had a 
lower mitotic index compared to BRAF-FLVE-induced tumors (Figure 2.5A) (Robinson et 
al., 2010). Immunostaining for the cellular proliferation marker Ki-67 demonstrated 
generally lower cellular proliferation in BRAF-KD tumors compared to BRAF-FLVE 
tumors which were consistently highly proliferative (Figure 2.5). 
Similar to the BRAF-FLVE-induced tumors, there was considerable heterogeneity 
between tumors within the same sections; some were composed mainly of spindle cells 
while others were predominantly epithelioid. Several tumors also contained populations of 
giant tumor cells (Figure 2.6A). Immunostaining using a C-terminal antibody for BRAF 
and for the HA-epitope tag confirmed expression of virally delivered BRAF-KD. All of 
the tumors expressed Nestin, and GFAP expression was present in several smaller tumors 
(Figure 2.6B). Together, the lower mitotic index, the lower MAPK activation, and the more 
circumscribed tumor borders may explain the lack of symptoms observed in these mice at 
12 weeks postinjection as compared to BRAF-FLVE-induced tumors. These distinct 
features suggest that the tumors driven by BRAF-KD have a later onset or more indolent 
behavior than tumors driven by BRAFV600E (Robinson et al., 2010). 
2.3.4 MEK and PI3K/mTOR inhibition reduces proliferation and induces 
significant apoptosis in cells expressing the BRAF-KD. Type 1 BRAFV600E mutant 
inhibitors (vemurafenib, dabrafenib) have been demonstrated to cause paradoxical 





2013). Since activating mutations in BRAF drives cell growth and proliferation primarily 
through canonical MAPK signaling (e.g., BRAF-MEK–ERK), we chose to test the effect 
of Mek inhibition on the growth of cell lines driven by BRAF-FLVE and BRAF-KD. The 
concentration required for the inhibition of Erk phosphorylation with the Mek inhibitor 
PD0325901 (hereafter 901) in N-TVA;Ink4a/Arf-/- astrocytes expressing BRAF-FLVE and 
BRAF-KD, was determined by titration using 100 nmol/L and 1 µmol/L of 901. Treatment 
with 0.1µM significantly reduced Erk1/2 phosphorylation and 1 µM of the Mek inhibitor 
was sufficient for complete blockade (Figure 2.7A). As expected, we observed a negative-
feedback loop between Mek and PI3K signaling, evidenced by the increasing levels of P-
Akt with increasing Mek inhibition (Robinson et al., 2011); therefore,  we also targeted 
PI3K/mTOR signaling using 1 µmol/l of the PI3K/mTOR inhibitor NVP-BEZ235 
(hereafter; BEZ). The proliferation of Ink4a/Arf-/- astrocytes expressing BRAF-FLVE and 
BRAF-KD was significantly inhibited by both 901 and BEZ. Combined treatment with 901 
and BEZ produced an additive effect (S = 1.2, P = 0.0633)  in the context of the BRAF-KD 
and synergistic effect in the context of BRAFV600E (S = 0.516, P = 0.0001) as assessed by 
reduction in cell growth over 96 hours with synergy and additivity calculations performed 
as described previously (Figure 2.7B) (Robinson et al., 2011). A significant increase in 
apoptosis in BRAFV600E and BRAF-KD cells was also observed (Figure 2.7C). 
 
2.4 Discussion 
While the role of the N-terminal segment within BRAF fusion genes (i.e., 
KIAA1549, SRGAP3, FAM131b) is unknown, there is evidence to suggest their possible 





and contains a Fes/CIP4 Homology (FCH) domain, which has a putative function in 
regulating the microtubule cytoskeleton (Yang et al., 2006). KIAA1549 harbors two 
transmembrane domains, which have been proposed to tether RAF to the membrane. 
However, the minimal FAM131b fusion component is only 9 amino acids in size and has 
no known or predicted function (Cin et al., 2011). Our results demonstrate that the BRAF-
KD alone can cooperate with Ink4a/Arf loss to drive gliomagenesis in vivo. Deletion of the 
N-terminal autoinhibitory domain allows activation of the protein at sufficient levels to 
drive tumorigenesis. We suspect that the transforming capabilities of the various BRAF 
fusion genes lies within the BRAF-KD, and the promoters of FAM131b, SRGAP3, and 
KIAA1549 simply serve to direct expression to the appropriate cells in the brain. Thus, the 
result of the rearrangements is the loss of the regulatory domain leading to constitutive 
MAPK activation, a phenomenon that is observed in 80-90% of Pas (Jones et al., 2012). 
While it has been shown before that BRAF-KDVE can form lesions in mice resembling PA 
(Gronych et al., 2011), BRAF fusion genes in humans do not harbor the V600E mutation. 
To our knowledge, this is the first report to show that BRAF-KD can lead to glioma 
development in cooperation with Ink4a/Arf  loss. 
Expression of a powerful oncogene, such as BRAFV600E, in otherwise normal cells 
can prevent proliferation by inducing senescence; this phenomenon, referred to as 
‘Oncogene Induced Senescence’ (OIS), is especially common in melanoma, where it 
prevents the progression of benign nevi with BRAFV600E mutations into melanoma 
(Michaloglou et al., 2005). Loss of p16 expression is a common occurrence in melanoma 
and, interestingly, loss of p16 also correlates strongly with reduced senescence, increased 





2008; Horbinski et al., 2012). The BRAF-KD Ink4a/Arf-/- mice demonstrated no obvious 
symptoms within the 12-week experimental timeframe and survived to endpoint, in 
contrast to the BRAF-FLVE Ink4a/Arf-/- mice that began to die from the 3rd week. Other 
distinguishing characteristics between the BRAF-KD and BRAF-FLVE include histology 
showing a lack of necrosis and less invasive borders as well as immunoblotting 
demonstrating decreased levels of MAPK activation in tumors driven by the BRAF-KD. 
This suggests that the level of canonical BRAF signaling plays a role in glioma 
development and progression. Fascinatingly, expression of the full length 
KIAA1549:BRAF fusion protein has never been detected either in vitro or in vivo, even in 
KIAA1549:BRAF transgenic mice (Kaul et al., 2013), suggesting that sporadic PA require 
low levels of BRAF signaling, and that this is one way in which they may escape OIS in 
the context of p16 expression. Hereditary melanoma–astrocytoma syndrome is 
characterized by a dual predisposition to melanoma and development of low-grade 
paediatric astrocytomas. This syndrome is associated with germline mutations that effect 
only CDKN2A exon 1β, resulting in loss of p14 expression but not p16 expression 
(Randerson-Moor et al., 2001). For these reasons, future experiments will concentrate on 
determining the grade and response to treatment of tumors induced with BRAF-KD and 
either p16 or p14 loss. 
MEK inhibition in gliomas is an area of ongoing study. Currently, a clinical trial 
(NCT02124772) is underway to investigate the efficacy of treating V600E gliomas with a 
combination of a Trametinib and Dabrafenib. Recently, both drugs have shown limited 
penetration into the brain due to active efflux across the blood-brain-barrier (BBB) 





for 901 because it has been shown to penetrate the BBB (Barrett et al., 2008; Rice et al., 
2012). In fact, the toxic effects of 901 are likely due to its ability to cross the BBB. The 
paradoxical activation of the MAPK pathway caused by BRAFV600E inhibitors could be 
inhibited by dual BRAF-MEK inhibition as has been observed in melanoma, but the 
consequence of this is expected to be more p-AKT (Kudchadkar et al.). As proposed 
previously, we believe that a combination of 901 and BEZ can serve as a rational cancer 
therapeutic (Robinson et al., 2011). To date there have been no clinical trials studying the 
specific combination of BEZ and 901; however, two trials have examined the combined 
effect of dual inhibition MAPK and PI3K involving either BEZ or 901. NCT01337765 was 
a phase 1 trial for studying BEZ with a different MEK compound (MEK162), and 
NCT01347866 is a currently ongoing phase 1 trial to study 901 with another PI3K-mTOR 
compound (PF-05212384). 
In summary, our findings demonstrate that the BRAF-KD region of the numerous 
BRAF fusion genes drives gliomagenesis. As cancers with BRAF mutations are often 
addicted to this signaling pathway, targeting BRAF signaling represents a reasonable 
therapeutic strategy. However, cells expressing KIAA1549-BRAF fusions genes display 
paradoxical activation when they are targeted with BRAFV600E inhibitors (i.e., 
vemurafenib) (Schnetzke et al., 2013). Unfortunately, next generation, paradox breaker 
BRAF inhibitors that have reduced capacity to paradoxically activate wild-type BRAF do 
not inhibit BRAF fusions genes at physiologically relevant doses (Le et al., 2013; Sievert 
et al., 2013). We previously demonstrated that efficacy of combined MEK and 
PI3K/mTOR inhibition for the treatment of high-grade gliomas driven by BRAFV600E 





inhibition is a rational therapy for the treatment of gliomas driven by fusion genes 
containing the BRAF-KD as well. 
 
2.5 Materials and Methods 
2.5.1 Mice and genotyping. Nestin-TVA;Ink4a/Arflox/lox mice and genotyping 
procedures have been described (Robinson et al., 2010). The mice are on a mixed genetic 
background consisting of FVB/n, 129, and C57Bl/6. PCR genotyping for the TVA 
transgene and for the Ink4a/Arflox and wild-type Ink4a/Arf alleles was performed as 
described (Holmen and Williams, 2005; Robinson et al., 2010). All experiments were 
approved by the IACUC before experimentation. 
2.5.2 Establishment of N-TVA;Ink4a/Arflox/lox astrocytes in culture. N-
TVA;Ink4a/Arflox/lox primary astrocytes were established following dissection of newborn 
mouse brain tissue by physical disruption into single cells using scalpels and 0.25% trypsin. 
Cell cultures were maintained in RPMI (Invitrogen) containing 10% FBS, and gentamicin 
at 37°C. 
2.5.3 Viral constructs. The retroviral vectors used in this study are replication-
competent avian leukosis virus (ALV) long terminal repeat (LTR), splice acceptor, and 
Bryan polymerase-containing vectors of envelope subgroup A [designated RCASBP(A) 
and abbreviated RCAS]. RCASBP(A)CRE, RCASBP(A)BRAFV600E and 
RCASBP(A)KRASG12D have been previously described (Holmen and Williams, 2005; 
Robinson et al., 2010). RCASBP(A)BRAF-KD was created by PCR amplification from 
pcDNA3.1 BRAF template DNA, [a gift from Martin McMahon (UCSF)] followed by 





RCASBP(A) DV using LR Clonase Enzyme Mix (Invitrogen) (Forward: atggcgtacccat 
acgacgtcccagactacgctaaaacacttggtagacgggactc, Reverse: cagtggacaggaaacgcacca) per the 
manufacturer’s specifications. To propagate the RCAS viruses, proviral DNA was 
transfected into DF-1 cells grown at 39°C using the calcium phosphate transfection method 
(Kingston et al., 2003). RCAS vectors are replication-competent in the DF-1 cell line, an 
immortalized chicken fibroblast line, and high titer viral stocks can be obtained (Schaefer-
Klein et al., 1998). The supernatants were filtered through a 0.45-µm filter, and viral titers 
were determined as described (Smith et al.). 
2.5.4 Viral infections in vitro. Primary N-TVA;Ink4a/Arflox/lox astrocytes were 
seeded in 6-well plates at a density of 5 × 104 cells/well and were maintained in RPMI with 
5% FBS, gentamicin at 37°C as described previously (Robinson et al., 2010). After the 
cells attached, 1 mL of filtered virus-containing medium was added in the presence of 8 
µg/ml polybrene (Sigma) for 2 h at 37°C in 5% CO2. 
2.5.5 Growth in soft agar. To assess anchorage-independent growth, 1.5 × 105 cells 
were suspended in 0.35% Difco agar noble (Becton Dickinson) in RPMI with 10% FBS 
and layered over presolidified 0.65% Difco Noble Agar in RPMI with 10% FBS per well 
of a six-well dish. Each cell line was assayed in triplicate. 
2.5.6 Western blotting. Protein concentrations were determined using the Bio-Rad 
DC Protein Assay (Bio-Rad). The proteins were separated on a 4-20% Tris-glycine gradient 
polyacrylamide gel, transferred to nitrocellulose, and incubated for 1 h at room temperature 
in blocking solution (0.05% Tween-20 in Tris-buffered saline with 5% NFDM or 5% 
BSA). Blots were immunostained for the following antigens: phospho-Erk at 





tubulin (T9026, 1:5000, Sigma); HA epitope on BRAF-KD (HA.11, 1:1000, Covance); C-
terminus of BRAF (SC166, 1:500, Santa Cruz Biotechnology); and BRAFV600E (E1929, 
1:2000, Spring Bioscience). The blots were then incubated with an anti-mouse or anti-
rabbit IgG-HRP secondary antibody, incubated with ECL solution (Amersham), and 
exposed to film (Kodak). 
2.5.7 In vivo infection. Infected DF-1 cells from a confluent culture in a 10-cm dish 
were trypsinized, pelleted, resuspended in 50 µL PBS, and placed on ice. Newborn mice 
were injected intracranially 2 mm ventral from bregma (intersection of the coronal and 
sagittal sutures) with 5 µL of infected DF-1 cells using a gas-tight Hamilton syringe as 
described previously (Robinson et al., 2010, 2011). 
2.5.8 Histological analysis. Brain tissue from injected mice was fixed in 10% 
formalin, embedded in paraffin and 5-µm sections were adhered to glass slides. The 
sections were stained with hematoxylin and eosin or left unstained for 
immunohistochemistry (IHC). Images were captured using a Zeiss Axio microscope 
equipped with an AxioCam ICc3 camera (Zeiss). 
2.5.9 Immunohistochemistry. Tissue sections were deparaffinized and antigen 
retrieval was performed in ‘Diva Decloaking’ buffer (Biocare Medical) by boiling for 10 
min. Sections were treated with 3% H2O2 and blocked in Background Sniper (Biocare 
Medical) for 10 min. Primary antibodies were diluted in Renaissance background reducing 
diluent (Biocare Medical). Sections were incubated overnight at 4°C and probed with Mach 
4 rabbit polymer reagent (Biocare Medical) or Mach 4 mouse probe for 15 min followed 
by Mach 4 polymer for 15 min for mouse monoclonal antibodies. Visualization was carried 





Antibodies against the following antigens were used: GFAP (13-0300, 1:500, Invitrogen); 
synaptophysin (ab32127, 1:200, Abcam); BRAF-KD (detected using an antibody to the 
HA epitope (HA.11, 1:1000, Covance) and C-terminal BRAF antibody (SC166, 1:500, 
Santa Cruz Biotechnology)); Nestin (ab6142, 1:200, Abcam); phospho-Erk (4370, 1:100, 
Cell Signaling); and Ki-67 (M7246, 1:50, Dako,) using a rabbit anti-rat linker (P0450, 1:50, 
Dako). 
2.5.10 Drug treatment. To measure the effect of MEK inhibition on phosphorylated 
Erk (P-Erk) in astrocytes expressing BRAF constructs, drug was serially diluted in 10-fold 
increments in RPMI containing 2% FBS and added to cells in 6-well plates. 0.1% DMSO 
vehicle was added in negative control wells. After 1 h, cells were washed twice in PBS 
before analysis by Western blot. To measure the effect of the MEK inhibitor PD0325901 
or the PI3K/mTOR inhibitor NVP-BEZ235 on cell proliferation as measured by ATP 
levels, drug was diluted to 1.0 µM and added to astrocytes. After 96 h, ATP levels were 
detected using the ATPlite 1step Luminescence Assay System (Perkin Elmer), following 
the manufacturer’s instructions. In brief, 100µl of reconstituted ATPlite reagent was added 
to cells in a 96-well plate. The plate was incubated on an orbital shaker at 700rpm for 3 
min and dark-adapted for 10 min before luminescence was read for 0.1 sec per well on a 
Synergy HT multimode microplate reader (BioTek). To measure the effect of the MEK 
inhibitor PD0325901 or the PI3K/mTOR inhibitor NVP-BEZ235 on apoptosis, drugs were 
diluted to 1.0 µM and added to astrocytes. After 96 h, the cells were resuspended in Guava 
Viacount reagent (Millipore) and 5000 events per sample were read according to the 
manufacturer’s instructions, as described previously (Robinson et al., 2011). All drug 





2.5.11 Statistical analysis. Western blot density analysis was performed using 
Image J. Kaplan Meier survival data analysis and determination of synergy between 
PD032509 and NVP-BEZ235 were done as previously described (Robinson et al., 2011). 
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Figure 2.1 BRAF schematic. A: BRAFV600E B: KIAA1549:BRAF C: FAM131B-BRAF, 
showing FAM131B amino acids D: BRAF-kinase domain (BRAF-KD), showing amino 











Figure 2.2 Analysis of the expression and functional activity of the BRAF-KD in the 
context of Ink4a/Arf-deficiency. A: Western blot of Ink4a/Arf-deficient astrocytes 
(MC41+) infected with BRAF-KD (KD) and BRAFV600E (FLVE) with corresponding 
uninfected, negative control astrocytes (MC41-), and positive control avian fibroblasts (+). 
B: BRAF-KD expression causes MAPK activation as measured by P-Erk in BRAF-KD 
transfected human 293FT cells (+) compared to mock transfected cells (-). C: Relative 
proliferation of Ink4a/Arf-deficient astrocytes infected with BRAF-KD (KD) or 
BRAFV600E (FLVE) compared to uninfected, control cells. The mean of three replicates is 
shown with error bars for standard error. D: Colony formation of Ink4a/Arf-deficient 
astrocytes infected with BRAF-KD (KD) or BRAFV600E (FLVE) compared to uninfected, 

















Figure 2.3 Histological examination of brain sections from mice injected with 
Ink4a/Arf-deficient astrocytes expressing BRAF-KD. H&E: sections stained with 
hematoxylin and eosin. IHC for P-Erk demonstrates that the MAPK pathway is active in 
the tumor but not adjacent normal brain. Nestin and GFAP are glial specific markers. 
BRAF-KD expression was detected by IHC for the HA epitope tag on virally delivered 
BRAF or by using the C-terminal BRAF antibody. IHC sections were counterstained with 







Figure 2.4 Difference in survival of tumor-bearing mice between BRAF-KD and 
BRAF-FLVE. A: Incidence of tumor formation for BRAF-KD and BRAF-FLVE in Nestin-
TVA;Ink4a/Arflox/lox mice. B: Kaplan-Meier post-hoc survival analysis between BRAF-KD 
Ink4a/Arf-/- and BRAF-KD Ink4a/Arf-/- mice. C: Western blot comparing P-Erk levels 
between BRAF-KD Ink4a/Arf-/- and BRAF-FLVE Ink4a/Arf-/- astrocytes with corresponding 
quantification of P-Erk relative to total levels of Erk. Data are represented as mean ± S.E.M 












Figure 2.5 A comparison of cellular proliferation between brain sections from 
RCASBP(A) BRAF-KD & CRE injected and RCASBP(A) BRAFV600E & CRE 
injected mice. IHC for cellular proliferation marker Ki67 demonstrated that BRAFV600E 
tumors (A-C) were consistently highly proliferative while proliferation varied significantly 








Figure 2.6 Histological examination of brain sections from RCASBP(A) BRAF-KD 
and CRE injected mice. A: Representative low-power images of brain sections from 
tumor-bearing mice are shown. H&E: sections stained with hematoxylin and eosin. IHC 
for synaptophysin demonstrated that none of the tumors were neuronal in origin. Tumor A 
is representative of tumors that expresses the astrocyte maker GFAP while tumor B is an 
example that was negative for GFAP expression. Cells in tumor C possessed spindle cell 
morphology, while tumor B was more epithelioid, and tumor A was mixed as well as 
containing a population of large, nondividing giant cells. Scale bar represents 1mm. B: 
High-power histological examination of a GFAP expressing tumor. IHC for synaptophysin 
demonstrates that the tumors are not neuronal and expresses the astrocyte maker GFAP. 
BRAF-KD expression was detected by IHC for the HA epitope tag on virally delivered 
BRAF. IHC for P-Erk demonstrates that the MAPK pathway is active in the tumor but not 







Figure 2.7 Pharmacological inhibition of cells harboring mutant BRAF. A: MEK 
Inhibition with PD0325901 at 0 µM, 0.1 µM, and 1.0 µM for one hour in RPMI 2% FBS 
of Ink4a/Arf-deficient astrocytes infected with BRAF-KD (KD) and BRAFV600E (FLVE) 
with corresponding uninfected, negative control astrocytes. MEK inhibition decreases P-
Erk levels by western blot. B: Growth inhibition in Ink4a/Arf-deficient astrocytes infected 
with BRAF-KD (KD) and BRAFV600E (FLVE) treated in triplicate with 1 µmol/l PD0325901 
(901), 1 µmol/l NVP-BEZ235 (BEZ) or combination (BEZ/901) for 96 h. Cells treated 
with vehicle alone (DMSO) served as controls. Cell growth was measured using the 
ATPlite assay. Data was normalized to untreated controls and are represented as mean ± 
S.E.M.  C: Apoptosis induced by inhibition of MEK and PI3K/mTOR signaling in mouse 
astrocytes. Ink4a/Arf-deficient astrocytes infected with BRAF-KD (KD) and BRAFV600E 
(FLVE) were treated in triplicate with either DMSO as a control, 1 µmol/l PD0325901 (901), 
1 µmol/l NVP-BEZ235 (BEZ) or in combination (BEZ/901) for 96 h. Apoptosis was 




HBEGF MODELS THE CLASSICAL SUBTYPE OF 
 GLIOBLASTOMA IN THE CONTEXT OF  
INK4A/ARF AND PTEN LOSS  
THROUGH AXL AND EGFR 
 
3.1 Preface 
This chapter is a reformatted version of a manuscript submitted to Cancer 
Discovery in April 2016. The work presented herein was completed with the following 
coauthors: James P. Robinson, Joshua A. Sonnen and Sheri L. Holmen. 
 
3.2 Introduction 
Malignant gliomas, including anaplastic astrocytomas and glioblastomas (GBM), 
are aggressive tumors that confer a poor prognosis upon diagnosis (Louis et al., 2007; 
Ostrom et al., 2014). Anaplastic astrocytomas are characterized by high mitotic activity 
and cytological atypia. Glioblastomas retain the features of lower grade gliomas but 
additionally present with microvascular proliferation and/or pseudopalisading necrosis 
(Louis et al., 2007). With treatment, which consists of surgery, radiotherapy, and 
chemotherapy, the average survival for patients diagnosed with GBM is about 14 months 





underlying malignant glioma initiation and maintenance such that new targets can be 
identified and new therapies developed. 
Glioblastoma was the first cancer type to be systematically analyzed by The Cancer 
Genome Atlas (TCGA) network. An integrated genomic approach was used to identify 
numerous alterations in the disease (Brennan et al., 2013; Verhaak et al., 2010). Sequencing 
of these human malignant gliomas revealed several alterations in three core pathways. The 
receptor tyrosine kinase (RTK) – RAS – phosphatidylinositol-3-kinase (PI3K) pathway 
was altered in 88% of samples, the retinoblastoma (RB) pathway was altered in 78% of 
samples, and the p53 pathway was altered in 87% of samples (Brennan et al., 2013; 
Verhaak et al., 2010). In the RTK-RAS-PI3K axis, the most common alterations were 
mutation or amplification of epidermal growth factor receptor (EGFR) and homozygous 
deletion of phosphatase and tensin homolog deleted on chromosome ten (PTEN). In the 
p53 and RB pathways, the most common lesion was homozygous deletion of cyclin- 
dependent kinase 2A (CDKN2A), which encodes both p16INK4a and p19ARF. EGFR- 
amplified tumors, which account for 65% of glioblastomas, are often associated with 
increased expression of EGFR ligands including heparin-binding epidermal growth factor 
(EGF)-like growth factor (HBEGF) (Acquaviva et al., 2011; Mishima et al., 1998; 
Ramnarain et al., 2006). 
HBEGF has been associated with the progression of many solid tumors, including 
breast, pancreatic, and ovarian (He et al., 2015; Ray et al., 2013; Yotsumoto et al., 2010). 
In up to 40% of primary malignant gliomas, HBEGF has been shown to be co-expressed 
with EGFR by immunohistochemistry (Mishima et al., 1998; Ramnarain et al., 2006). 





to normal brain tissue (Mishima et al., 1998). In normal mouse astrocytes, HBEGF 
increases cell proliferation and nestin expression, a sign of dedifferentiation (Puschmann 
et al., 2014). HBEGF is also mitogenic in human glioma cell lines and this activity can be 
blocked with HBEGF-neutralizing antibodies (Mishima et al., 1998; Ramnarain et al., 
2006). In addition to activation of EGFR, HBEGF has been shown in bladder cancer cells 
to have other pleiotropic properties, including induction of matrix metalloproteinase 9 
(MMP9) and vascular endothelial growth factor (VEGF) expression, which allows for 
tumor invasion and proliferation (Ongusaha et al., 2004). In chicken fibroblasts, expression 
of HBEGF induces transformation (Fu et al., 1999). In U251 glioma cells, expression of 
EGFRvIII, the most common variant of EGFR, induces expression of HBEGF. Moreover, 
silencing of HBEGF decreases EGFRvIII-tumorigenicity in this context (Li et al., 2014; 
Ramnarain et al., 2006). However, the ability of HBEGF to promote transformation in 
astrocytes in vitro and induce or sustain gliomas in vivo has not been assessed. 
In the current study, we used the well-established RCAS/TVA glioma mouse model 
to assess the role of HBEGF in glioma development and maintenance in vivo. Compared 
to genetically engineered models, where every cell within a given tissue carries the genetic 
lesion, tumors generated using this model arise from a small number of cells within a 
normal microenvironment, which mimics the human disease. Furthermore, mammalian 
cells ectopically expressing the viral receptor TVA can be infected with several different 
RCAS viruses to allow the determination of the minimal components required for 
tumorigenesis. We demonstrate that HBEGF can promote tumor development in the 
context of either Ink4a/Arf and/or Pten loss. Furthermore, suppression of HBEGF 





suggests it may be a relevant target for therapy. Interestingly, we discovered that HBEGF 
signals through both Egfr and Axl in this context. While AXL has been implicated in 
glioblastoma formation, it has not been previously reported to play a role in HBEGF signal 
transduction (Hutterer et al., 2008; Vajkoczy et al., 2006). Therefore, our findings have 
important implications for the treatment of glioblastoma. 
 
3.3 Results 
3.3.1 Overexpression of HBEGF correlates with decreased survival in GBM 
patients. To assess the effect of ligand overexpression on patient survival, we compared 
the median survival among cohorts of patients whose tumors overexpressed one of seven 
different EGFR ligands. We observed that patients harboring malignant gliomas that 
overexpressed HBEGF had a median survival of only 7.4 months, which was significantly 
shorter than the median survival of 13.6 months in patients with malignant gliomas that did 
not overexpress HBEGF (Table 3.1). This suggests that overexpression of HBEGF confers 
a worse prognosis in these patients. Although HBEGF has been shown to increase the 
proliferation of human glioma cells in vitro (Mishima et al., 1998), little is known about 
the role of this ligand in the biology of malignant gliomas. 
3.3.2 HBEGF promotes anchorage-independent growth. To evaluate the role(s) 
of specific genes in glioma initiation, progression and maintenance, we and others have 
used a somatic-cell gene delivery method based on the RCAS/TVA retroviral vector 
system and successfully induced malignant gliomas in vivo (Robinson et al., 2010; Van 
Brocklin et al., 2012). Using this established model system, we initially assessed the ability 





These astrocytes were infected with RCAS-Cre alone or in combination with either RCAS-
HBEGF and/or RCAS-EGFR. Following confirmation of HBEGF and EGFR expression 
(Figure 3.1A), the ability of the astrocytes to grow in an anchorage-independent manner 
was assessed by growth in soft agar. These astrocytes were immortalized by deletion of 
Ink4a/Arf to allow for ease of growth in culture but they are not transformed, as evidenced 
by the lack of colonies detected in the Nestin-TVA;Ink4a/Arf-/- astrocytes without EGFR 
or HBEGF infection (Figure 3.1B). Anchorage-independent growth was detected in 
astrocytes expressing HBEGF (P < 0.001). While colonies were also observed when EGFR 
was expressed in the absence of HBEGF, they were significantly fewer in number than was 
observed in astrocytes expressing HBEGF (P = 0.01). No significant difference in colony 
number was observed between astrocytes expressing HBEGF alone or co-expressing 
EGFR (P = 0.2). This suggests that HBEGF was the limiting factor in this context because 
the addition of exogenous EGFR did not significantly increase colony formation. EGFR 
activity was confirmed by adding known quantities of HBEGF (0ng/ml, 0.5ng/ml and 
5.0ng/ml) to astrocytes either without (-) or with exogenous receptor (EGFR) (Figure 
3.1C). Dose-dependent phosphorylation of EGFR (Y1068), as well as activation of 
downstream targets, including Akt (S473) and Erk1/2 (T202/204), was observed. 
3.3.3 Expression of HBEGF results in reduced survival in vivo in the context of 
Ink4a/Arf or Pten loss. To evaluate the effect of HBEGF expression in nestin-expressing 
cells in vivo, we utilized Nestin-TVA;Ink4a/Arflox/lox mice and generated both Nestin-
TVA;Ptenlox/lox and Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice. Exons 2 and 3 of the 
Ink4a/Arf locus are flanked by LoxP sites such that in the absence of Cre these mice express 





p19Arf nonfunctional (Aguirre et al., 2003). Exon 5 of the Pten locus is flanked by LoxP 
sites such that in the absence of Cre, these mice express normal levels of Pten. Cre-
mediated excision eliminates exon 5, which encodes for a region of Pten that is essential 
for its phosphatase activity (Zheng et al., 2008). Delivery of Cre alone did not result in a 
decrease in survival within the experimental time point of 16 weeks in any of the strains 
evaluated (Figure 3.2B and Table 3.2). Intracranial delivery of viruses containing HBEGF 
and Cre in Nestin-TVA;Ink4a/Arflox/lox mice resulted in a mean survival of 68.5 ± 21.2 days, 
whereas expression of HBEGF and Cre resulted in a mean survival of 56.1 ± 11.8 days in 
Nestin-TVA;Ptenlox/lox mice and 28.7 ± 2.3 days in Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox 
mice (Figure 3.2A and Table 3.2). A significant difference in mean survival was observed 
between each of these cohorts (P < 0.05) (Figure 3.2A). 
3.3.4 Addition of exogenous EGFR does not enhance the effect of HBEGF in 
vivo. Although a significant difference was not observed in soft-agar colony formation 
when exogenous EGFR was co-expressed with HBEGF, there may be enhanced signaling 
in vivo. We pursued this possibility by delivering RCAS-EGFR along with RCAS-Cre and 
RCAS-HBEGF in Nestin-TVA;Ink4a/Arflox/lox, Nestin-TVA;Ptenlox/lox, and Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox mice. The median survival for these cohorts was not 
significantly different than the same cohorts that lacked exogenous EGFR (P > 0.1) (Figure 
3.2A, Figure 3.2B, and Table 3.2). 
3.3.5 HBEGF-expressing mouse tumors histologically resemble human 
malignant gliomas. Brain sections were examined following necropsy and were scored as 
no tumor, low-grade tumor, and high-grade tumor based on histological features apparent 





atypia, including hyperchromasia and pleomorphism, while high grade tumors also 
exhibited mitotic figures, vascular proliferation, and areas of pseudopalisading necrosis 
(Figure 3.3A and Figure 3.3B). Seventy-five percent of the tumors were high grade when 
both Ink4a/Arf and Pten were lost, while only 36% were high grade with Pten loss alone. 
No high-grade tumors were observed with loss of Ink4a/Arf alone, but 45% of mice 
developed low-grade tumors in this cohort. No tumors were observed in brain sections of 
mice injected only with HBEGF or Cre (Figure 3.3C and Table 3.2). Virally delivered 
HBEGF was detected in all tumors using immunohistochemistry (IHC) (Figure 3.3A). Loss 
of Ink4a/Arf and Pten were also confirmed with immunohistochemistry (Figure 3.4). All 
tumors also expressed the astrocyte marker glial fibrillary acidic protein (GFAP) and the 
neural progenitor cell marker nestin, though less staining was observed in the tumors with 
loss of Ink4a/Arf alone (Figure 3.3A). Assessment by IHC of the proliferative marker Ki67 
showed that tumors lacking Pten or Pten and In4a/Arf were more proliferative than tumors 
lacking only Ink4a/Arf (P < 0.03) (Figure 3.3B and Figure 3.3D). Tumor penetrance 
correlated with mean survival; cohorts with combined Ink4a/Arf and Pten loss displayed 
the highest penetrance (100%), followed by those with Pten loss (90%) and Ink4a/Arf loss 
(45%) (Figure 3.2A and Figure 3.3C). 
3.3.6 EGFR and AXL mediate HBEGF signaling in mouse astrocytes. To 
determine if HBEGF signals through other RTKs, we performed an unbiased approach 
using the R&D Proteome Profiler, a membrane-based antibody array, which detects 
phosphorylation of 39 mouse receptor tyrosine kinase receptors simultaneously. Isogenic 
astrocytes from Nestin-TVA;Ink4a/Arflox/lox mice were infected with either RCAS-Cre or 





lysed, and subjected to the Proteome Profiler immunoassay. As expected, Egfr was 
phosphorylated in the presence of HBEGF (Figure 3.5A and Figure 3.6). Interestingly, the 
only other RTK that was differentially phosphorylated was Axl (Figure 3.5 and Figure 3.6). 
To ascertain the functional significance of Axl phosphorylation in this context, we used 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing 
to delete Egfr and/or Axl in the mouse astrocytes. Guide RNAs specific for mouse Egfr 
and Axl were designed and expressed in vectors containing resistance genes for blasticidin 
and puromycin, respectively. Single-cell clones were selected and expanded. Gene editing 
and loss of expression were confirmed through high-resolution melt analysis (HRMA), 
sequencing, and western blot (Figure 3.5B). Because the guide RNAs are specific for the 
mouse genome, we performed rescue experiments using the human orthologs of EGFR and 
AXL (Figure 3.5B). Anchorage-independent growth was assessed by soft agar assay in this 
context. Cells lacking either Egfr, Axl, or both had significantly fewer colonies than the 
positive control. Interestingly, loss of Egfr alone had significantly fewer colonies than loss 
of Axl alone (Figure 3.5C). Expression of human EGFR and/or AXL was able to partially 
rescue the single knockouts and completely rescue the double knockout in the anchorage-
independent growth assay (Figure 3.5C). 
3.3.7 HBEGF-driven mouse GBM most closely resembles the classical subtype 
of human GBM. Human GBM has been classified into four different subtypes: proneural, 
classical, mesenchymal, and neuronal (Verhaak et al., 2010). High-grade HBEGF-driven 
tumors in mice resemble human GBM histologically (Figure 3.3A and Figure 3.7A), but it 
is unclear which subtype, if any, they model. To determine if HBEGF-driven GBM 





TVA;Ink4a/Arflox/lox;Ptenlox/lox mice by delivery of RCAS-Cre and RCAS-HBEGF. In 
addition, in the same mouse strain, gliomas were generated with RCAS-Cre in combination 
with RCAS-PDGFA or RCAS-BRAFV600E, other drivers previously found to form high-
grade gliomas (Figure 3.7A) (Ozawa et al., 2014; Robinson et al., 2010). Previously, 
gliomas driven by PDGFA in the context of Ink4a/Arf and Pten loss were shown to 
resemble the proneural subtype using microarray bead chip technology (Ozawa et al., 
2014). RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue 
that had been histologically confirmed by a board-certified Neuropathologist (J.A.S.). 
Three tumors from each cohort along with brain tissue from six control Nestin-TVA-
negative Ink4a/Arflox/lox;Ptenlox/lox mice were analyzed by RNA sequencing from a Ribo-
Zero treated library (Figure 3.8A). The transcript coverage and exonic mapping rate were 
typical for FFPE tissue (Figure 3.8B and Figure 3.8C). The sample cross correlation heat 
map shows that each of the tumor replicates clustered with each other and the controls 
clustered separately from the tumors (Figure 3.8A). The transcriptome of each cohort was 
compared to the TCGA GBM subtype classifier genes after converting those genes to their 
mouse orthologs. The highest correlation for HBEGF was with the classical subtype (r = 
0.14), for PDGFA was the proneural subtype (r = 0.30), for BRAF was the mesenchymal 
subtype (r = 0.47), and for the control was the neural subtype (r = 0.26), as shown on the 
heat map (Figure 3.7B). Although the correlation values are relatively low, the results 
replicated the proneural classification for PDGFA-driven tumors as previously described 
(Ozawa et al., 2014). 
In both our in vitro and in vivo assays evaluating the oncogenic potential of 





EGFR (Figure 3.1B and Figure 3.2B). This suggests that endogenous EGFR is sufficient 
when HEBGF is overexpressed or that an alternative signaling pathway could be possible. 
The Proteome Profiler and CRISPR knockout functional studies suggest a role for Axl in 
HBEGF signaling (Figure 3.5A and Figure 3.5C). Differential expression analysis in the 
tumors from RNA sequencing showed specific upregulation of Egfr and Axl transcripts in 
HBEGF tumors (Figure 3.9). In PDGFA-driven tumors, there was specific upregulation of 
Pdgfra (Figure 3.9). These results were confirmed with real-time PCR for Axl and Egfr on 
the same tumor samples (Figure 3.7C). HBEGF-driven tumors had a 10-fold increase in 
Egfr transcript and 6-fold increase in Axl transcript compared to healthy controls and 
PDGFA-driven tumors (P value < 0.03). HBEGF-directed expression of EGFR likely 
explains why endogenous EGFR was sufficient both in vitro and in vivo. 
3.3.8 Suppression of HBEGF expression results in tumor regression and 
increased survival in vivo. In vitro neutralizing antibodies that recognize HBEGF decrease 
the proliferation of cultured glioma cells, suggesting that HBEGF is important for tumor 
cell maintenance (Mishima et al., 1998; Ramnarain et al., 2006; Sato et al., 2012). 
Translating these findings in vivo is complicated by pharmacological limitations in drug 
kinetics and perfusion across the blood-brain barrier. To bypass these limitations, we 
utilized a genetic approach to determine whether HBEGF is required for tumor 
maintenance in vivo. We have previously described the generation of a viral vector that 
allows expression of inserted genes to be regulated postdelivery using the tet-regulated 
system (Holmen and Williams, 2005). A tet-responsive element (TRE) was inserted 
immediately downstream of the envelope gene in the replication-competent avian retroviral 





driven from this promoter and not the viral LTR. Expression from the TRE requires the 
presence of a tetracycline transcriptional activator (tTA) such as tet-off or a reverse tTA 
(rtTA) such as tet-on. In the context of tet-on, the tet-responsive gene is expressed only in 
the presence of doxycycline (Dox); in the context of tet-off, the tet-responsive gene is 
repressed in the presence of Dox (Kistner et al., 1996). In the context of tet-off expression 
in vitro, we observed HBEGF expression that was effectively suppressed by the 
administration of Dox (Figure 3.10A). 
Tumors were generated in Nestin-TVA;Ink4a/Arflox/lox and Nestin-TVA;Ptenlox/lox 
mice with retroviruses containing TRE-HBEGF, tet-off, and Cre and confirmed with MRI 
imaging at 21 days of age. In the Nestin-TVA;Ink4a/Arflox/lox mice, tumor-bearing mice 
were split into two cohorts, one receiving standard feed (n = 9) and one receiving Dox feed 
(n = 10). While the mean survival in the untreated mice was 43.0 ± 7.9 days, the mean 
survival in the mice treated was 103.7 ± 4.9 days (P < 0.001) (Figure 3.10B). In the Nestin-
TVA;Ptenlox/lox mice, tumor-bearing mice were divided into two cohorts, one receiving 
standard feed (n = 11) and one receiving Dox feed (n = 15). While the mean survival in the 
untreated mice was 46.8 ± 6.5 days, all Dox-treated mice survived to the experimental 
endpoint of 112 days (P < 0.001) (Figure 3.10C). Consistent with the survival analysis, 
40% of the tumor-bearing Nestin-TVA;Ink4a/Arflox/lox mice experienced tumor regression 
detectable by MRI, while all of the tumor-bearing Nestin-TVA;Ptenlox/lox mice showed no 
evidence of disease (Figure 3.10D and Figure 3.10E). We have previously demonstrated 
that Dox has no innate tumor suppressive properties; therefore, tumor regression is due to 
inhibition of HBEGF expression in this context (Robinson et al., 2011). 





newborn Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice led to the formation of high-grade 
tumors in all injected mice (Figure 3.11A). To evaluate the kinetics of virally delivered 
HBEGF expression and activity following Dox treatment, we treated mice with Dox for 3 
days. Expression of HBEGF as detected by IHC was visible without Dox treatment; 
however, following 72 hours of Dox treatment very little HBEGF expression was visible 
by IHC (Figure 3.11A). A significant difference was observed in the mean number of cells 
staining positively for the proliferation marker Ki67 between the mice that received 
standard feed and the mice that received Dox feed. While 41.4 ± 4.3 Ki67 positive cells 
were detected per HPF in the untreated tumor samples, 5.7 ± 1.2 Ki67 positive cells were 
detected per HPF in the samples treated with Dox for 72 hours (P = 0.02) (Figure 3.11B). 
MRI was performed at 21 days of age to identify tumor-bearing mice and to monitor 
tumor growth or regression at multiple time points throughout the study. One cohort of 
tumor-bearing mice received standard feed (n = 16) and the other cohort received Dox feed 
continuously starting at 21 days of age (n = 10). Survival rates were compared between 
untreated mice and mice given Dox to determine whether the suppression of HBEGF 
expression increased survival. While the mean survival in the untreated mice was 23.9 ± 
0.8 days, the mean survival in the mice treated starting at 21 days was 83.9 ± 7.7 days (P 
< 0.001), with one mouse still alive at the experimental endpoint of 16 weeks (Figure 
3.11C).  This mouse remains tumor-free by MRI at 20 weeks of age (Figure 3.12A). To 
assess tumor maintenance in more advanced tumors, another cohort received Dox feed 
starting at 28 days of age (n = 10) (Figure 3.11C). The mean survival in the mice treated 
starting at 28 days was 62.0 ± 7.5 days, which was significantly different from the untreated 





mean survival compared to the mice treated at 21 days (P = 0.02), demonstrating that earlier 
treatment increases survival. 
3.3.9 Recurrent tumors develop in the absence of HBEGF expression in the 
context of Ink4a/Arf and Pten loss. Tumors recurred in 19 / 20 responding Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox mice while on Dox treatment. The MRI data from a 
representative mouse that developed recurrent disease while on Dox treatment is shown in 
Figure 3.12B. A small tumor is visible before Dox treatment but no tumor was visible at 
28, 42, or 64 days; however, tumor recurrence was visible starting at 84 days and a large 
recurrent tumor was detected at 104 days. Brain tissue was examined and H&E analysis 
confirmed GBM in this mouse. Of evaluable mice with recurrent tumors, 50% re-expressed 
HBEGF and 50% recurred in the absence of HBEGF expression (Figure 3.11D and Figure 
3.13). Future studies will evaluate the mechanism(s) of resistance in tumors that recurred 
in the absence of HBEGF expression. 
 
3.4 Discussion 
Using an established mouse model of glioma (Robinson et al., 2010), we assessed 
the sufficiency of HBEGF in gliomagenesis. While not sufficient on its own, HBEGF 
cooperates with Ink4a/Arf or Pten loss to promote gliomagenesis. To our knowledge, this 
is the first report showing that HBEGF can lead to malignant glioma development in this 
context. Comparison of the HBEGF tumors to the human subtype signatures show that they 
most closely resemble the classical subtype (Verhaak et al., 2010). We also show that 
previously published mouse models for PDGFA and BRAFV600E resemble the proneural 





Verhaak et al., 2010). 
We have observed that in astrocytes in vitro, HBEGF activates not only Egfr but 
also Axl, a member of the TAM family of RTKs. AXL has been shown to be upregulated 
in human glioma cell lines and tissue, but activation of AXL in the presence of HBEGF 
has not previously been reported in gliomas or other cancers (Hutterer et al., 2008; 
Vajkoczy et al., 2006). Although unreported in the context of HBEGF, a role for AXL in 
mediating EGFR signaling has been cited as a mechanism of resistance against targeted 
EGFR therapies in lung and breast cancer (Liu et al., 2009; Zhang et al., 2012). It is thought 
that there is a physical interaction between the two receptors, allowing for transactivation 
that permits enhanced, diversified downstream signaling. It is possible that HBEGF 
activates AXL via transactivation from an activated EGFR receptor. This phenomenon has 
been reported in breast cancer cells, where AXL was found to co-immunoprecipitate with 
EGFR (Meyer et al., 2013). 
While determination of the initial events in the genesis of a glioma are biologically 
important, it is perhaps more important clinically to ascertain the conditions for tumor 
maintenance to help guide clinical intervention. As an initial step toward developing 
targeted therapies, we used a tetracycline-regulated system to control HBEGF expression 
to assess the necessity of HBEGF in sustaining tumor growth. We demonstrated increased 
mean survival in all cohorts of mice after inhibition of HBEGF. While half of the tumors 
in the Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice recurred due to re-activation of HBEGF, 
half recurred in the absence of HBEGF expression. Future studies will evaluate the 
mechanism(s) of resistance in these tumors. Our study suggests that HBEGF not only 





suggests that it is a good target for therapy. 
 
3.5 Materials and Methods 
3.5.1 Mice and genotyping. Nestin-TVA;Ink4a/Arflox/lox, Nestin-TVA;Ptenlox/lox, 
Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice were generated from pre-existing strains (kind 
gifts of Eric Holland, Ronald DePinho, and Marcus Bosenberg). The mice are on a mixed 
genetic background consisting of FVB/n, 129, and C57Bl/6. PCR genotyping for the TVA 
transgene and for the Ink4a/Arflox, wild-type Ink4a/Arf, Ptenlox, and wild-type Pten alleles 
was performed as previously described (Cho et al., 2015). All experiments were approved 
by the IACUC before experimentation. For treatment studies, diet containing 625 mg/kg 
of doxycycline was used (Envigo Teklad TD.08434). 
3.5.2 Cell culture. Nestin-TVA;Ink4a/Arflox/lox primary astrocytes were established 
by physical disruption of newborn mouse brains into single cells using scalpels and 0.25% 
trypsin. Cell cultures were maintained in RPMI (Invitrogen) containing 10% FBS and 0.5% 
gentamicin at 37°C with 5% CO2. To disrupt Egfr and Axl via CRISPR gene editing, 
astrocytes were infected with VSV-G-pseudotyped plenti-CRISPRv2-Egfr (target: 
CCTCCATTAGACCATCCAGG) containing blasticidin resistance and/or plenti-
CRISPRv2-Axl (target: CAGGTGCCAGAGGACTCACG) containing puromycin 
resistance. Clones were selected using 2.5 µg/ml puromycin and/or 80 µg/ml blasticidin. 
Both CRISPR-Cas9 constructs were generated by the Mutation Generation and Detection 
(MGD) core at the University of Utah. Clones were first screened with high-resolution melt 
analysis (HRMA) with the following primers: EGFR-HF (CTCCTGGACCCACTTCTT 





CTGGGTGTTATC), and AXL-HR (CCAGGGAATATCACAGGTGCCA) and then 
edited candidates were confirmed with sanger sequencing EGFR-SF (GTGGGAGT 
CACAGCACGTTAAA), EGFR-SR (TCACTTACCAAGGCTGACTGGA), AXL-SF 
(TATCACAAGCTCAGAGCCACGT), AXL-SR (ATCCCAGGCCTTCTTCCTAACA) 
followed by western blot analysis. 
3.5.3 Viral constructs. The avian retroviral vectors used in this study are either 
replication-competent Avian Leukosis Virus (ALV) long terminal repeat (LTR) splice 
acceptor Bryan polymerase subgroup A [RCASBP(A)] or replication-competent ALV 
LTR no splice acceptor Bryan polymerase subgroup A [RCANBP(A)], hereafter referred 
to as RCAS and RCAN, respectively. RCAS-CRE and RCAS-TETOFF have previously 
been described (Van Brocklin et al., 2012). RCAS-HBEGF and RCAN-TRE-HBEGF were 
created by PCR amplification from pcDNA3-proHB-EGF-CS (Addgene #11601) using 
AGCTTGGTACCGAGCTCG and GTCAATGGTGATGGTGATGAT primers, followed 
by TOPO cloning into the Gateway entry vector pCR8 (Invitrogen) and recombination into 
RCAS-DV or RCAN-DV using LR Clonase Enzyme Mix (Invitrogen). RCAS-EGFR and 
RCAS-AXL were also cloned using LR recombination from the Human Kinase ORF Kit 
(Addgene Kit #1000000014). RCAS-PDGFA was cloned using LR recombination from 
the Gateway PLUS shuttle X03795.1 (Genecopoeia). RCAS-BRAFV600E has been 
described previously (Robinson et al., 2010). To propagate the viruses, proviral DNA was 
transfected into DF-1 cells, an immortalized chicken fibroblast line, grown at 39°C using 
the calcium phosphate transfection method. RCAS vectors are replication-competent in the 






3.5.4 In vitro infection. Primary astrocytes were seeded in 6-well plates at a density 
of 5 × 104 cells/well and maintained in RPMI with 10% FBS and 1% gentamicin at 37 °C. 
After the cells attached, 1 mL of filtered virus-containing medium was added in the 
presence of 8 µg/ml polybrene (Sigma) for 3 h at 37°C in 5% CO2 and repeated on three 
consecutive days. 
3.5.5 Soft Agar assay. To assess anchorage-independent growth, 1.5 × 105 cells 
were suspended in 0.35% Difco Noble Agar (Becton Dickinson) in RPMI with 10% FBS 
and layered over presolidified 0.65% Difco Noble Agar in RPMI with 10% FBS per well 
of a six-well dish. Each cell line was assayed in triplicate following 1µg/µl nitroblue 
tetrazolium stain (Invitrogen) added 200 µl overnight. 
3.5.6 Western blotting. Protein concentrations were determined using the Bio-Rad 
DC Protein Assay (Bio-Rad). The proteins were separated on 4-20% or 8-16% Tris-glycine 
gradient polyacrylamide gels, transferred to nitrocellulose, and incubated for 1 h at room 
temperature in blocking solution (0.05% Tween-20 in Tris-buffered saline with 5% NFDM 
or 5% BSA). Blots were immunostained for the following antigens: phospho-Erk at 
Thr202/Tyr204 (#4370, 1:1000, CST); total Erk (#9102, 1:1000, CST); vinculin (#4650, 
1:1000, CST); H3 (#4499, 1:2000, CST); phosphor-Egfr (#3777, 1:1000, CST); Egfr 
(#4267, 1:1000, CST); Axl (#4977, 1:1000, CST); and HBEGF (#AF-259-NA, 1:500, 
R&D). The blots were then incubated with an anti-mouse or anti-rabbit IgG-HRP 
secondary antibody as appropriate, incubated with ECL solution (Amersham), and exposed 
to film (Kodak). 
3.5.7 R&D Proteome Profiler RTK-Array. Astrocytes were serum-starved 





Array Kit (R&D). After binding of lysate with detection antibody and subsequent washing, 
array membranes were chemiluminescently detected with film (Kodak). The arrays were 
quantitated by densitometry using Image J. 
3.5.8 In vivo infection. Infected DF-1 cells from a confluent culture in a 10-cm dish 
were trypsinized, pelleted, resuspended in 50 µL PBS, and placed on ice. Newborn mice 
were injected intracranially 2 mm ventral from bregma (intersection of the coronal and 
sagittal sutures) with 5 µL of infected DF-1 cells using a gas-tight Hamilton syringe as 
described previously (Robinson et al., 2010). 
3.5.9 Histological analysis. Brain tissue from injected mice was fixed in 10% 
formalin, embedded in paraffin, and 4-µm sections were adhered to glass slides. The 
sections were stained with hematoxylin and eosin or left unstained for 
immunohistochemistry (IHC). Images were captured using a Zeiss Axio microscope 
equipped with an AxioCam ICc3 camera (Zeiss). 
3.5.10 Bioinformatics and genomics. TCGA glioblastoma survival data were 
accessed through the cBioPortal (Cerami et al., 2012). For RNAseq analysis, tumors were 
microdissected from 10 µm FFPE sections and extracted using the Ambion Recoverall Kit 
(Ambion). Samples were prepped by the High-throughput Genomics Core at University of 
Utah with TruSeq Stranded Total RNA with Ribo-Zero Gold and then sequenced with 
HiSeq 50 Cycle Single-Read Sequencing v4 (Illumina). Reads were aligned to the mouse 
genome (mm10) and differential gene expression were determined with the open source 
USeq/DESeq2 package by the Bioinformatics Analysis core at the University of Utah. 
Genes were selected using two thresholds, an FDR of <10% and absolute log2 ratio > 1. 





mouse orthologues genes using Biomart (Ozawa et al., 2014; Verhaak et al., 2010). Tumor 
and control variance normalized expression data (rlog values) were converted to median-
centered log2 fold change and compared to the TCGA classifier genes using pairwise 
Pearson correlations. 
3.5.11 Immunohistochemistry. Tissue sections were deparaffinized and antigen 
retrieval was performed in Rodent Decloaker (Biocare Medical) by boiling at 120 °C for 
10 min. Sections were treated with 3% H2O2 and blocked in Rodent Block M (Biocare 
Medical) for 30 min. Primary antibodies were diluted in Renaissance background reducing 
diluent (Biocare Medical). Sections were incubated overnight at 4 °C and probed with 
Mach 4 HRP-polymer, Mouse-on-Mouse HRP-polymer, Rat-on-Mouse HRP-polymer or 
Goat-on-Rodent HRP-polymer (Biocare Medical) for 30 min. Visualization was carried 
out with Betazoid DAB (Biocare Medical). Sections were counterstained with 
hematoxylin. Antibodies against the following antigens were used: GFAP (#13-0300, 
1:200, Invitrogen), Pten (#M3627, 1:150, Dako), p19ARF (#MA1-16664, Invitrogen), 
synaptophysin (#ab32127, 1:200, Abcam), Nestin (#ab6142, 1:250, Abcam), HBEGF 
(#AF-259-NA, 1:250, R&D) and Ki-67 (#M7246, 1:100, Dako). 
3.5.12 Magnetic resonance imaging. Mice were anesthetized using 2% isoflurane 
with oxygen (1 L/min). A 50 µl bolus of MultiHance (Bracco) MRI contrast was injected 
intraperitoneally 15 min before scanning. A fast gradient-echo three-plane localizer for 
graphical prescription preceded acquisition of contrast-enhanced images on a 7T Bruker 
MRI using a T1-weighted multislice multiecho (MSME) sequence, as previously described 






3.5.13 Statistical analysis. Western blot and RTK array density analysis were 
performed using Image J. Survival data analysis was done using a log-rank test of the 
Kaplan Meier estimate of survival. To compare means, two-tailed Student’s t test was used. 
P values below 0.05 were considered significant. 
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Table 3.1 HBEGF is associated with decreased survival. Median survival of GBM 
patients from the TCGA dataset with or without upregulation of known EGFR ligands with 
associated logrank p-value from cBioPortal. The EGFR ligands listed are epidermal growth 
factor (EGF), heparin-binding EGF-like growth factor (HBEGF), transforming growth 




















Table 3.2 Survival data for in vivo studies. Mean survival of TVA positive, tumor-
bearing mice in three different strains of Nestin-TVA mice: Ink4a/Arflox/lox, Ptenlox/lox, and 
Ink4a/Arflox/lox;Ptenlox/lox that have been injected with different combinations of RCAS 
viruses containing Cre, HBEGF or EGFR. E.E. denotes that all mice survived to the 












Figure 3.1 HBEGF promotes anchorage-independent growth of immortal astrocytes. 
A: Expression of EGFR and HBEGF in DF1 cells and Nestin-TVAInk4a/Arf-null mouse 
astrocytes.  B: Soft agar colony formation of Ink4a/Arf-null astrocytes expressing 
exogenous EGFR and/or HBEGF compared with RCAS-Cre infected control cells. Data 
are represented as mean ± S.E.M. C: Western blot analysis of downstream effector 
pathways in Ink4a/Arf-null astrocytes expressing either endogenous (-) or exogenous 
(EGFR). HBEGF was added to serum-free media at two different concentrations (0.5 ng/ml 







Figure 3.2 HBEGF cooperates with loss of Ink4a/Arf and Pten to promote glioma 
formation. A: Kaplan-Meier survival analysis of Nestin-TVA;Ink4a/Arflox/lox (n = 11, long 
dash), Nestin-TVA;Ptenlox/lox (n = 11, short dash), and Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox (n = 12, round dash) mice injected with viruses containing 
HBEGF and/or Cre was compared with injection of viruses containing HBEGF alone in 
Nestin-TVA;Ink4a/Arflox/lox (n = 10, solid line)  B: Kaplan-Meier survival analysis of 
Nestin-TVA;Ink4a/Arflox/lox (n = 12, long dash), Nestin-TVA;Ptenlox/lox (n = 12, short dash), 
and Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox (n = 12, round dash) mice injected with viruses 
containing HBEGF, EGFR, and Cre compared with injection of viruses containing Cre 







Figure 3.3 Histological examination of brain sections from injected mice. A: 
Representative H&E and HBEGF, GFAP, Nestin, and Ki67 immunohistochemistry images 
of HBEGF-driven tumors from each strain of mice injected with viruses containing 
HBEGF and Cre. Scale bar represents 300 µm. B: Representative high-power H&E and 
Ki67 images of HBEGF-driven tumors from each strain of mice injected with viruses 
containing HBEGF and Cre. Scale bar represents 300µm. C:  Percentage of each tumor 
grade observed in Nestin-TVA;Ink4a/Arflox/lox, Nestin-TVA;Ptenlox/lox, and Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox mice injected with viruses containing HBEGF alone or in 
combination with Cre. Low grade (LG) tumors were characterized by nuclear atypia and 
pleomorphism while high grade tumors (HG) were characterized by the presence of 
necrosis, vascular proliferation, and mitotic figures.  D. Quantification of Ki-67 
proliferation index for HBEGF-driven tumors. For each tumor, the average of four high-







Figure 3.4 Confirmation of Ink4a/Arf and Pten loss in tumors following delivery of 
Cre. Viral delivery and expression of Cre recombinase was confirmed by 
immunohistochemistry using antibodies against p19Arf and Pten in tumors induced with 
with RCAS-HBEGF and RCAS-Cre in A: Nestin-TVA;Ink4a/Arflox/lox mice B: Nestin-
TVA;Ptenlox/lox mice, and C: Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice. Scale bar 







Figure 3.5 Both Egfr and Axl mediate HBEGF signaling. A: Phosphorylation of 
multiple RTKs was simultaneously assayed in isogenic astrocytes in the presence (+) or 
absence (-) of HBEGF. A subset of RTKs analyzed representing the ErbB and TAM family 
members are shown. Data are represented as mean ± S.E.M. B.  Endogenous Axl and/or 
Egfr expression was eliminated using CRISPR-mediated gene editing (-) in Nestin-
TVA;Ink4a/Arf-null astrocytes . Human AXL and EGFR were expressed following RCAS-
mediated infection for rescue (+). The arrow represents the AXL band. C. Astrocytes from 
B were assayed for soft-agar colony formation to determine the functional significance of 







Figure 3.6 HBEGF activates Egfr and Axl. A: Isogenic astrocytes in the presence (+) or 
absence (-) of HBEGF were assayed for phosphorylation of different RTKs in parallel. 
Increased phosphorylation in the presence of HBEGF was only seen for Egfr (B1,B2) and 
Axl (B19, B20). B. Coordinates for the RTK arrays shown in A. C. Key for the different 







Figure 3.7 Molecular comparison between mouse and human GBM. A: Representative 
H&E sections for high-grade gliomas derived in the Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox 
mouse model using RCAS-Cre and three different drivers: BRAFV600E(i., ii., iii.), PDGFA 
(iv., v., vi.), and HBEGF (vii., viii., ix.) showing 4x, 10x and 40x magnification, 
respectively. Scale bar represents 300µm. B: Heatmap showing Pearson correlations 
between the TCGA subtypes (proneural, neural, classical, mesenchymal) and high-grade 
mouse gliomas driven by RCAS-BRAFV600E, PDGFA, and HBEGF in the absence of 
Ink4a/Arf and Pten. C: Real-time PCR analysis of Axl, Egfr, Pdgfra mRNA levels in either 
HBEGF or PDGFA tumors. Rn18s was used as an endogenous reference. Relative 









Figure 3.8 RNA-Seq Metrics. A: Cluster heatmap for intrasample variability displayed as 
a distance matrix based on raw counts from individual samples generated with the USeq 
package Defined Region Differential Seq (DRDS).	 High-grade gliomas derived in the 
Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mouse model using RCAS-Cre and three different 
drivers: BRAFV600E, PDGFA, and HBEGF were compared to TVA negative controls. B: 
5¢ to 3¢ coverage for all transcripts calculated with the Picard tool, CollectRNASeqMetrics. 








Figure 3.9 RNA-Seq read coverage data for HBEGF and PDGFA driven tumors. A: 
Relative transcript levels for Axl across three replicates of healthy TVA negative controls, 
three HBEGF-driven tumors, and three PDGFA-driven tumors derived in the Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox mouse model. RNA sequencing read coverage was 
generated from the USeq utility Sam 2 USeq and visualized with the Integrative Genomics 
Viewer. B: Same as in A but for Egfr. C: Fold change in Axl and Egfr transcript comparing 
tumor samples to healthy controls from RNA sequencing. Log2 ratios were calculated from 
the combined replicates. FDR is a log transformed p-value from DRDS, where the p value 







Figure 3.10 Suppression of HBEGF expression in vitro and in vivo. A: Western blot of 
isogenic astrocytes infected with TRE-HBEGF and/or tet-off with or without 2 µg/ml of 
doxycycline for 72 h. B: Kaplan-Meier survival analysis of tumor-bearing Nestin-
TVA;Ink4a/Arflox/lox injected with RCAN-TRE-HBEGF, RCAS-tet-off, and RCAS-Cre 
that were not treated (n = 9, round dash) and treated starting at 21 days of age (n = 21, solid 
line). C: Same as in B but for Nestin-TVA;Ptenlox/lox injected with RCAN-TRE-HBEGF, 
RCAS-tet-off, and RCAS-Cre (n = 11, round dash) (n=21, solid line). D: MRI showing 
initial regression of RCAN-TRE-HBEGF tumors in Nestin-TVA;Ink4a/Arflox/lox mice after 
doxycycline treatment starting at 21 days of age and subsequent resistant tumors at 103 
days of age. The abbreviation d.o. represents days old. E: MRI showing initial regression 
of RCAN-TRE-HBEGF tumors in Nestin-TVA;Ptenlox/lox mice after doxycycline treatment 







Figure 3.11 Suppression of HBEGF expression prolongs survival in vivo. A: 
Immunohistochemical analysis of HBEGF and Ki67 in brain tissue isolated from Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox mice injected with RCAN-TRE-HBEGF, RCAS-tet-off, and 
RCAS-Cre that were either untreated or treated with doxycycline for 3 days. Scale bar 
represents 300 µm. B: The Ki67 staining was quantified using two representative tumors 
for each cohort. For each tumor, the average of four high-power fields is shown. Data are 
represented as mean ± S.E.M. C: Kaplan-Meier survival analysis of Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox injected with RCAN-TRE-HBEGF, RCAS-tet-off, and 
RCAS-Cre that were not treated (n = 16, round dash), treated starting at 21 days of age (n 
= 10, solid line), or treated starting at 28 days of age (n = 10, short dash). D: 
Immunohistochemical analysis of regressed tumors using antibodies against HBEGF and 







Figure 3.12 MRI analysis. A: MRI showing regression of RCAN-TRE-HBEGF tumors 
in Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice after doxycycline treatment starting at 21 
days of age and no evidence of disease at 104 days of age. The abbreviation d.o. represents 
days old. B: MRI from a mouse showing a tumor at 21 days of age, followed by initial 











Figure 3.13 HBEGF expression in regressed tumors. A: Immunohistochemical analysis 
of regressed tumors using an antibody against HBEGF for Nestin-
TVA;Ink4a/Arflox/lox;Ptenlox/lox injected with RCAN-TRE-HBEGF, RCAS-tet-off, and 
RCAS-Cre that were doxycycline treated. These regressed tumors showed no HBEGF 











4.1 Chapter Summaries 
 In Chapter 2, the tumorigenic properties of the BRAF fusion genes observed in 80% 
of pilocytic astrocytomas were shown to be due to the C-terminal kinase domain (Jones et 
al., 2009). This finding is supported by in vitro functional data in colony formation assays 
of Nestin-TVA mouse astrocytes. When astrocytes expressing the BRAF kinase domain 
were injected orthotopically in syngeneic mice, highly cellular and invasive gliomas that 
lacked malignant properties such as necrosis and endothelial hyperplasia were observed. 
As a complementary approach, the BRAF kinase domain was delivered with the RCAS 
retrovirus allowing for somatic cell gene transfer into TVA-expressing neural progenitor 
cells in vivo. All of the mice lived to the experimental endpoint of 12 weeks. Histological 
analysis of brain tissue from these mice revealed tumors in 21% of the mice in the context 
of Ink4a/Arf loss. These tumors were well circumscribed and had a lower mitotic index 
compared to tumors driven by expression of full-length BRAFV600E (Robinson et al., 2010). 
These results establish that the BRAF-KD alone can cooperate with Ink4a/Arf loss to drive 
gliomagenesis in vivo and that the transforming properties of the different BRAF fusion 
genes lie within the kinase domain of BRAF. Thus the N-terminal portion of the fusions 





appropriate cells in the brain. As BRAFV600E inhibitors activate rather than inhibit the 
BRAF fusion genes, combined MEK and PI3K/mTOR inhibition was used and showed 
great efficacy in astrocytes expressing the BRAF kinase domain in nanomolar 
concentrations. This is a marked improvement over the 10µM concentration needed for the 
second-generation BRAF inhibitors (Sievert et al., 2013).  
In Chapter 3, HBEGF, which is co-expressed with EGFR in a subset of malignant 
gliomas, was demonstrated to promote the development of gliomas of varying grades in a 
context-specific manner (Mishima et al., 1998; Ramnarain et al., 2006). In immortalized 
but nontransformed mouse astrocytes, expression of activated HBEGF led to the formation 
of colonies in soft agar. Using the RCAS-TVA system, expression of HBEGF in Ink4a/Arf-
deficient mice led to the formation of low-grade gliomas with a penetrance of 54%. When 
HBEGF was expressed in a Pten-deficient background, high-grade tumors were observed 
with an overall glioma penetrance of 90%. Co-expressing exogenous EGFR did not impact 
colony formation in vitro or tumor formation in vivo, so the possibility of alternative 
signaling pathways was pursued. Using a proteome profiler, activation of Axl in mouse 
astrocytes expressing HBEGF was discovered, and the functional significance of this 
activation was confirmed through CRISPR-mediated gene editing. Using RNA sequencing 
and qPCR, we discovered that Egfr and Axl are transcriptionally upregulated by HBEGF. 
This likely explains why exogenous EGFR was redundant in this context. 
Expression profiling of the HBEGF tumors was done in conjunction with the 
RCAS-TVA glioma models for PDGFA and BRAFV600E. These tumors were then 
compared to the TCGA subtypes (Ozawa et al., 2014; Robinson et al., 2010; Verhaak et 





the mesenchymal, proneural, and classical subtypes, respectively. In addition, the healthy 
control samples derived from injected TVA-negative mice showed similarities to the neural 
subtype, which is defined by the expression of neuronal markers. With the validation of 
the role of HBEGF in the initiation of gliomas, a tetracycline-inducible model for HBEGF 
in tumor maintenance was developed. In the context of Pten loss, no resistant tumors 
developed by the standard 16-week endpoint in the absence of HBEGF expression. In 
contrast, in the context of Ink4a/Arf loss, resistant tumors were observed, suggesting that 
Ink4a/Arf loss promotes tumor recurrence following HBEGF inhibition.  
 
4.2 Preview of Appendices 
 Appendix A concerns the analysis of the HBEGF-driven tumors that were co-
injected with a functional EGFR receptor. If EGFR were critical for gliomagenesis in this 
context, we would have expected to observe exogenous EGFR expression in the majority 
of the tumors. As virally delivered EGFR is HA epitope-tagged, it could be distinguished 
from endogenously expressed Egfr using immunohistochemistry. We observed that 57% 
(4 / 7) of Ink4a/Arf-deficient tumors, 60% (3 / 5) of Pten-deficient tumors, and 28% (2 / 7) 
of Ink4a/Arf- and Pten-deficient tumors expressed exogenous EGFR. In Chapter 3, survival 
of mice injected with HBEGF and mice injected with both HBEGF and EGFR were 
compared, but no significant difference was observed. Loss of Ink4a/Arf and Pten with 
EGFR overexpression did not result in tumor formation. With HBEGF co-overexpression, 
exogenous EGFR expression was detected in some of the tumors, but the latency of these 
tumors was not different from those that only expressed endogenous levels of Egfr. 





evaluating the role of AXL in HBEGF signaling. As observed with EGFR co-expression, 
co-expression of AXL in HBEGF-driven tumors did not affect survival. AXL was also C-
terminally tagged with HA, and 40% (2 / 5) of Ink4a/Arf-deficient tumors, 12% (1 / 8) of 
Pten-deficient tumors, and 41% (5 / 12) of Ink4a/Arf- and Pten-deficient tumors were 
found to express virally delivered AXL. With the caveat of relatively small numbers in 
each cohort, it appears that the selection pressure for expression of exogenous EGFR in 
HBEGF-driven tumors is stronger than that for AXL. In addition, EGFR was expressed the 
highest in Ink4a/Arf-deficient tumors, which were lower grade gliomas, while AXL was 
expressed the highest in Ink4a/Arf- and Pten-deficient tumors, which were higher grade 
gliomas. The expression of exogenous AXL in these tumors as well as preliminary co-
immunoprecipitation data support the role of AXL in HBEGF-mediated signaling outlined 
in Chapter 3. However, as observed for EGFR, the latency of these tumors was not different 
from those that only expressed endogenous levels of Axl. 
 Appendix C describes unpublished data with the role of PDGFA in gliomagenesis. 
In vitro studies were carried out in PDGFA-expressing astrocytes similar to the work done 
with HBEGF. Interestingly, when the investigation shifted towards in vivo work, it was 
found that PDGFA alone was sufficient to initiate gliomas and that loss of Ink4a/Arf or 
PTEN did not significantly affect gliomagenesis. The sufficiency of PDGFA alone was 
more apparent when its cognate receptor PDGFRA was co-injected, as the addition of 
PDGFRA actually increased survival. When expression of PDGFRA was assessed in all 
mice that were co-injected with PDGFA and PDGFRA, 29% (10 / 34) showed strong 
staining. Furthermore, the tumors that were positive for exogenous PDGFRA expression 





 Appendix D outlines ongoing work to develop an inducible model for BRAFV600E-
driven gliomas. Several attempts in the lab previously failed to produce viable virus that 
could confer expression of full-length mutant BRAF. It was suspected that the size of 
BRAF was too large to fit into the retrovirus capsid, so a lentiviral vector approach was 
pursued. This led to the creation of the TzTOC-BRAFV600E vector, which contains two 
independent promoters. The tetracycline-responsive promoter controls expression of 
mutant BRAF while a separate CMV promoter controls expression of the tetracycline 
transactivator, tet-off, and Cre recombinase. Although the vector worked in vitro and in 
vivo, an alternative approach was sought because of low penetrance and the long latency 
of tumor formation. The tumors derived through the lentiviral TzTOC vector were 
confirmed to express mutant BRAF. Currently, a new RCAN vector with a modified, 
shorter tet-responsive element is being utilized with promising in vitro results. Mice are 
currently being bred to do the in vivo validation. 
 
4.3 Perspectives for Future Work 
 The work presented in the previous chapters outlines an investigation of two 
oncogenic drivers, BRAF and HBEGF, with a thorough characterization of key tumor 
suppressors that cooperate with these drivers to induce gliomas in vivo. Exciting work 
remains in the potential therapeutic applications for these tumors that will hopefully impact 
the treatment of patients. 
In the inducible HBEGF model, there are still doxycycline-responsive tumors at 6 
months. These are the same mice in the 60% of responders that were reported in chapter 3. 





further with longitudinal MRI scans for evidence of tumor recurrence. For the tumors that 
have recurred, future work will be directed at elucidating the mechanism of resistance using 
both candidate and unbiased approaches.  
 As most pilocytic astrocytomas do not contain Ink4a/Arf loss, it would be 
worthwhile to derive tumors with intact Ink4a/Arf. No tumors were seen within the 12-
week period, so an extension of the experimental endpoint would be the next logical step. 
In addition, a continuation of the validation of targeting the kinase domain of BRAF with 
MEK and PI3K inhibitors in vivo would be another exciting future direction.  
 
4.4 Conclusion 
 The main focus of the Holmen lab is to define essential targets for human cancers 
through the development of preclinical mouse models. In line with this goal, the work in 
this dissertation investigates the role of mutant BRAF and HBEGF in the initiation and 
maintenance of gliomas using an in vivo model. The essential role of the kinase domain of 
BRAF was defined using both a transplantation model of astrocytes as well as a somatic 
cell gene transfer system, which afforded the use of MEK and PI3K inhibition as candidate 
therapy. Using those same tools, the role of HBEGF in glioma formation was also 
investigated. The use of CRISPR-mediated gene editing, RTK proteomics, and RNA 
sequencing defined a novel involvement of AXL in HBEGF-mediated signaling that has 
therapeutic implications. With an inducible model of HBEGF gliomagenesis, a new target 








Jones, D.T.W., Kocialkowski, S., Liu, L., Pearson, D.M., Ichimura, K., and Collins, V.P. 
(2009). Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to 
KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. 
Oncogene 28, 2119–2123. 
 
Mishima, K., Higashiyama, S., Asai, A., Yamaoka, K., Nagashima, Y., Taniguchi, N., 
Kitanaka, C., Kirino, T., and Kuchino, Y. (1998). Heparin-binding epidermal growth 
factor-like growth factor stimulates mitogenic signaling and is highly expressed in human 
malignant gliomas. Acta Neuropathol. 96, 322–328. 
 
Ozawa, T., Riester, M., Cheng, Y.K., Huse, J., Squatrito, M., Helmy, K., Charles, N., 
Michor, F., and Holland, E.C. (2014). Most human non-GCIMP glioblastoma subtypes 
evolve from a common proneural-like precursor glioma. Cancer Cell 26, 288–300. 
 
Ramnarain, D.B., Park, S., Lee, D.Y., Hatanpaa, K.J., Scoggin, S.O., Otu, H., Libermann, 
T. a, Raisanen, J.M., Ashfaq, R., Wong, E.T., et al. (2006). Differential gene expression 
analysis reveals generation of an autocrine loop by a mutant epidermal growth factor 
receptor in glioma cells. Cancer Res. 66, 867–874. 
 
Robinson, J.P., VanBrocklin, M.W., Guilbeault,  a R., Signorelli, D.L., Brandner, S., and 
Holmen, S.L. (2010). Activated BRAF induces gliomas in mice when combined with 
Ink4a/Arf loss or Akt activation. Oncogene 29, 335–344. 
 
Sievert, A.J., Lang, S., Katie, L., Madsen, P.J., Slaunwhite, E., Choudhari, N., Kellet, M., 
Storm, P.B., Resnick, A.C., Kjetland, E.F., et al. (2013). Paradoxical activation and RAF 
inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. 
Proc. Natl. Acad. Sci. 110, 8750–8750. 
 
Verhaak, R.G.W., Hoadley, K. a, Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, 
C.R., Ding, L., Golub, T., Mesirov, J.P., et al. (2010). Integrated genomic analysis 
identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in 


































Figure A.1 Expression of EGFR in HBEGF-driven tumors in the context of Ink4a/Arf 
loss. Representative H&E and HA immunohistochemistry images of HBEGF-driven 
tumors in Nestin-TVA;Ink4a/Arflox/lox mice injected with viruses containing HBEGF, Cre, 



















Figure A.2 Expression of EGFR in HBEGF-driven tumors in the context of Pten loss. 
Representative H&E and HA immunohistochemistry images of HBEGF-driven tumors in 
Nestin-TVA;Ptenlox/lox mice injected with viruses containing HBEGF, Cre, and HA-tagged 















Figure A.3 Expression of EGFR in HBEGF-driven tumors in the context of Ink4a/Arf 
and Pten loss. Representative H&E and HA immunohistochemistry images of HBEGF-
driven tumors in Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice injected with viruses 
















Figure A.4 Comparison of HBEGF-driven tumors with and without exogenous EGFR 
expression. Kaplan-Meier survival analysis of Nestin-TVA;Ink4a/Arflox/lox, Nestin-
TVA;Ptenlox/lox, and Nestin-TVA;Ink4a/Arflox/lox; Ptenlox/lox mice injected with viruses 
containing HBEGF, EGFR, and Cre with confirmed expression of exogenous EGFR (n = 
9, round dash) compared with injection of viruses containing HBEGF and Cre alone (n = 

































Figure B.1 Survival analysis of different cohorts of Nestin-TVA mice injected with 
HBEGF, Cre and/or AXL. Kaplan-Meier survival analysis of Nestin-TVA;Ink4a/Arflox/lox 
(n = 5, long dash, P = 0.0315), Nestin-TVA;Ptenlox/lox (n = 8, short dash, P = 0.002), and 
Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox (n = 12, round dash, P < 0.001) mice injected with 
viruses containing HBEGF, AXL, and Cre compared with injection of viruses containing 


















Figure B.2 Expression of AXL in HBEGF-driven tumors in the context of Ink4a/Arf 
loss. Representative H&E and HA immunohistochemistry images of HBEGF-driven 
tumors in Nestin-TVA;Ink4a/Arflox/lox mice injected with viruses containing HBEGF, Cre, 















Figure B.3 Expression of AXL in HBEGF-driven tumors in the context of Pten loss. 
Representative H&E and HA immunohistochemistry images of HBEGF-driven tumors in 
Nestin-TVA;Ptenlox/lox mice injected with viruses containing HBEGF, Cre, and HA-tagged 










Figure B.4 Expression of AXL in HBEGF-driven tumors in the context of Ink4a/Arf 
and Pten loss. Representative H&E and HA immunohistochemistry images of HBEGF-
driven tumors in Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice injected with viruses 
















Figure B.5 Comparison of HBEGF-driven tumors with and without exogenous AXL 
expression. Kaplan-Meier survival analysis of Nestin-TVA;Ink4a/Arflox/lox, Nestin-
TVA;Ptenlox/lox, and Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice injected with viruses 
containing HBEGF, AXL, and Cre with confirmed expression of exogenous AXL (n = 8, 
round dash) compared with injection of viruses containing HBEGF and Cre alone (n = 34, 









Figure B.6 Co-immunoprecipitation of EGFR and AXL. A: Dynabeads Co-IP assay 
was performed on 293FT cells that were transfected with plasmids encoding Myc-tagged 
AXL and HA-tagged EGFR. Normalized cell lysates were subjected to IP using protein A 
bound to anti-EGFR or anti-AXL antibodies. Input cell lysates, co-IP wash collections, and 
co-IP elutions were analyzed by western blotting using anti-EGFR and anti-AXL 
antibodies. Black arrow denotes band corresponding to EGFR while gray arrow denotes 
band corresponding to AXL. B: Same as in A except cells were treated with BS3 
(bis(sulfosuccinimidyl)suberate), a water-soluble, membrane-insoluble N-hydroxy-
succinimide ester to crosslink surface proteins. C: Same as in B except normalized cell 






























Figure C.1 PDGFA promotes anchorage-independent growth of immortal astrocytes. 
A: Expression of PDGFRA and PDGFA in DF1 cells and Nestin-TVAInk4a/Arf-null 
mouse astrocytes.  B: Soft agar colony formation of Ink4a/Arf-null astrocytes expressing 
exogenous PDGFRA and/or PDGFA compared with RCAS-Cre infected control cells. 
Data are represented as mean ± S.E.M. C: Western blot analysis of downstream effector 
pathways in Ink4a/Arf-null astrocytes expressing either endogenous (-) or exogenous 
(PDGFRA). PDGFA was added to serum-free media at two different concentrations (0.5 







Figure C.2 PDGFA cooperates with loss of Ink4a/Arf and Pten to promote glioma 
formation. A: Kaplan-Meier survival analysis of Nestin-TVA;Ink4a/Arflox/lox (n = 8, long 
dash, P = 0.0998), Nestin-TVA;Ptenlox/lox (n = 15, round dash, P = 0.0205), and Nestin-
TVA;Ink4a/Arflox/lox; Ptenlox/lox (n = 8, short dash, P = 0.228) mice injected with viruses 
containing PDGFA and/or Cre were compared with injection of viruses containing PDGFA 
alone in Nestin-TVA;Ink4a/Arflox/lox (n = 16, solid line).  B: Kaplan-Meier survival analysis 
of Nestin-TVA;Ink4a/Arflox/lox (n = 13, long dash, P < 0.001), Nestin-TVA;Ptenlox/lox (n = 
9, round dash, P = 0.00697), and Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox (n = 12, short dash, 
P = 0.168) mice injected with viruses containing PDGFA, PDGFRA, and Cre compared 
with injection of viruses containing PDGFA and PDGFRA in Nestin-TVA;Ink4a/Arflox/lox 















Figure C.3 Expression of PDGFRA in PDGFA-driven tumors. Representative H&E 
and HA immunohistochemistry images of PDGFA-driven tumors in Nestin-TVA mice 











Figure C.4 Expression of PDGFRA in PDGFA-driven tumors in the context of 
Ink4a/Arf loss. Representative H&E and HA immunohistochemistry images of PDGFA-
driven tumors in Nestin-TVA;Ink4a/Arflox/lox mice injected with viruses containing 















Figure C.5 Expression of PDGFRA in PDGFA-driven tumors in the context of Pten 
loss. Representative H&E and HA immunohistochemistry images of PDGFA-driven 
tumors in Nestin-TVA;Ptenlox/lox mice injected with viruses containing PDGFA, Cre, and 


















Figure C.6 Expression of PDGFRA in PDGFA-driven tumors in the context of 
Ink4a/Arf and Pten loss. Representative H&E and HA immunohistochemistry images of 
PDGFA-driven tumors in Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice injected with viruses 
















Figure C.7 Comparison of PDGFA-driven tumors in the presence or absence of 
exogenous PDGFRA expression. Kaplan-Meier survival analysis of Nestin-
TVA;Ink4a/Arflox/lox, Nestin-TVA;Ptenlox/lox, and Nestin-TVA;Ink4a/Arflox/lox; Ptenlox/lox 
mice injected with viruses containing PDGFA, PDGFRA, and Cre with confirmed 
expression of exogenous PDGFRA (n = 9, round dash) compared with injection of viruses 






























Figure D.1 Suppression of BRAFV600E expression in vitro. A: TzTOC-BRAFV600E is a 
lentiviral vector with two promoters, a tetracycline-responsive promoter upstream of the 
HA-tagged BRAFV600E and another constitutively active promoter upstream of 3x-FLAG 
tagged tet-off and c-Myc tagged Cre linked with a P2A, a peptide with a cis-acting 
hydrolase element for bicistronic expression. Western blot of Nestin-TVAInk4a/Arf-null 
mouse astrocytes infected with TzTOC-BRAFV600E or TzTOC-empty vector with or 
without 2 µg/ml of doxycycline for 72 h. B: Western blot of Nestin-TVAInk4a/Arf-null 
mouse astrocytes infected with TRE3-BRAFV600E and tet-off with or without 2 µg/ml of 
doxycycline for 72 h. C: Western blot of tet-off expressing DF1 chicken fibroblasts 
















Figure D.2 Inducible BRAFV600E cooperates with loss of Ink4a/Arf and Pten to 
promote glioma formation but with lower penetrance compared with RCAS-
BRAFV600E. Kaplan-Meier survival analysis of Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice 
injected with RCAS-BRAFV600E and RCAS-Cre (n = 11, round dash) compared to mice 
injected with TzTOC-BRAFV600E pseudotyped with EnvA (n = 18, long dash, P < 0.001) 
and mice injected with TzTOC-BRAFV600E pseudotyped with VCT, a chimeric receptor 















Figure D.3 Confirmation of HA-tagged BRAFV600E expression in BRAFV600E-driven 
tumors in the context of Ink4a/Arf and Pten loss. A: Representative H&E and HA 
immunohistochemistry images of BRAFV600E-driven tumors in Nestin-TVA; 
Ink4a/Arflox/lox;Ptenlox/lox mice after delivery of TzTOC-BRAFV600E pseudotyped with VCT, 
a chimeric receptor between VSV-G and EnvA. Scale bars represent 300 µm. B: Same as 
in A but for BRAFV600E-driven tumors in Nestin-TVA;Ink4a/Arflox/lox;Ptenlox/lox mice after 
delivery of TzTOC-BRAFV600E pseudotyped with EnvA.  
 
